From aches and pains to hormonal disorders, depression, anxiety and even immunity-related disorders, these non-invasive, alternative therapies promise to heal from within, slowly but surely, minus the side-effects of allopathic medicines. Heres more on three popular therapies.

This ancient eastern practice that originated in China found itself in the spotlight a decade ago when singers Celine Dion and Mariah Carey claimed it played a vital role in helping them conceive. Both gave birth to twinsafter much struggle due to their respective health issueswithout having to resort to IVF. But while the western world may have just recently woken up to the benefits of acupuncture, the Japanese and the Chinese have been using this therapy for decades now, treating everything from aches and pains to allergies, migraines, anxiety and even various hormonal disorders.

So what exactly is this form of treatment? Traditionally used to balance energy flow, acupuncture involves inserting very thin needles at strategic points of your body. Its essentially a drugless, natural treatment with no side effects, which works on the concept of Yin and Yang. Energy blockages are identified and worked upon, and balance in the body is restored for its optimal functioning, says Mumbai-based Dr Santosh Pandey, a PhD in alternative medicine. It is particularly helpful for inflammation or pain, as inserting a needle into a specific location can cause a release of endorphins, which are chemicals that your body produces to promote self-healing. Since it activates pain-killing hormones, it can treat acute or chronic pain.

Acupuncture sessions usually require anywhere from two sessions to 30 and more to show results, depending on the severity of the mental and/or physical issue being treated. If you suffer from chronic liver problems or issues with clotting, its best to avoid this therapy, cautions Dr Pandey.

Naturopathy, says Arizona-based Naturopathy physician Dr Meghna Thacker, believes in the healing power of nature. The body has an inherent capacity to heal itself and in many cases, without any treatment at all. With an increasing number of people preferring a holistic approach to health and wellness, this alternative and now broadly integrative medicinal practice is fast gaining traction.

So whats the basic tenet behind it? The aim, says Dr Thacker, is to first do no harm. The idea is to try healing the patient with natural and non-invasive therapies. For example, if a patient is dealing with an infection, if I can treat him or her with botanical or microbial medicines, that would be my preference over antibiotics, she adds.

In her recent book, Amazon bestseller, Seven Steps To Heal Your Thyroid, Dr Thacker explains in depth the science behind naturopathy. We treat the patient as a whole and not just that one particular issue. We identify the root cause and underlying reasons. The focus on this kind of therapy is also to prevent diseasesthere a so many factors that need to be looked at to ensure overall good health, she says.

Among the popular treatments is the bio-identical hormone replacement therapy (BHRT), which is different from the standard hormone therapies offered by modern medicine. In BHRT, we use natural plant-based prescription medicines to help patients transition from perimenopausal to postmenopausal years, explains Dr Thacker, who also specialises in thyroid treatment, adrenal support, nutrient IV therapy in addition to emotional wellness.

Several celebrities, including Kate Hudson, Gwyneth Paltrow and Cameron Diaz, have taken to social media to tout the benefits of this Japanese healing technique. And, despite the bad press it often receives for having little scientific data to back up the results, youll find many, especially in India, swearing by it. Reiki uses the bodys chakras to transfer healing energy to a recipient, working on the not just the body, but the mind and soul as well, says Mumbai-based Reiki grandmaster, certified numerologist and multi-modality Vannee Jaising, It can help you solve mental, physical as well as emotional issues, provided the recipient is open to receiving the healing energy."

Jaising, a conduit of this healing energyhas seen a surge in clients over the last few months, with COVID-19 and the consequent lockdowns and economic crisis pushing people on the brink of a meltdown. Reiki does not require physical touch. I can administer this healing to anyone, in any part of the world, and it will work, she explains, adding that this healing energy practice is free of side effects, making it safe for all. There are, of course, newer and more powerful modalities available nowReconnective Healing, Merkaba, Lama Fera, Humkara with Haleem, to name a few.

"Reiki can easily be your go-to first aid kitinstead of popping in a crocin to cure that headache, try this practice first to heal yourself. The benefits of spiritual healing are aplenty and much needed in this pandemic era, says Jaising.

How to use self-acupressure to help heal stress and burnout

Reiki for glowing skin? Ancient healing rituals are now finding place in modern skincare

6 natural remedies that can help manage pain before you reach for the painkiller

See the rest here:
From reiki to acupuncture: How alternative therapies can help you manage pain and balance your mood - VOGUE India

Recommendation and review posted by Bethany Smith

Abstract

Objective To evaluate the association between pregravid use of a variety of contraceptive methods and subsequent fecundability.

Design Prospective cohort study.

Setting Denmark and North America, 2007-19.

Participants 17954 women who had tried to conceive for up to six menstrual cycles at study entry. At baseline, participants reported their contraceptive histories, and personal, medical, and lifestyle characteristics.

Main outcome measures Pregnancy, determined by bimonthly follow-up questionnaires for up to 12 months.

Results Approximately 38% (n=6735) of participants had recently used oral contraceptives, 13% (n=2398) had used long acting reversible contraceptive methods, and 31% (n=5497) had used barrier methods. Women who had recently stopped using oral contraceptives, the contraceptive ring, and some long acting reversible contraceptive methods experienced short term delays in return of fertility compared with users of barrier methods. Use of injectable contraceptives was associated with decreased fecundability compared with use of barrier methods (fecundability ratio 0.65; 95% confidence interval 0.47 to 0.89). Users of injectable contraceptives had the longest delay in return of normal fertility (five to eight menstrual cycles), followed by users of patch contraceptives (four cycles), users of oral and ring contraceptives (three cycles), and users of hormonal and copper intrauterine devices and implant contraceptives (two cycles). Lifetime length of use of hormonal contraceptive methods was not associated with fecundability.

Conclusions Use of some hormonal contraceptive methods was associated with delays in return of fertility, with injectable contraceptives showing the longest delay. The findings indicated little or no lasting effect of long term use of these methods on fecundability.

Worldwide, about 22% of women of reproductive age used hormonal contraception in 2019.1 In the United States, 35% of women of reproductive age used hormonal contraception in 2015-17.2 Although male condoms and oral contraceptives remain the most commonly used methods in North America and Europe,1 long acting reversible contraceptive methods have become increasingly popular.2 Long acting reversible contraceptive methods include intrauterine devices, implants, and injectable contraceptives.3 In the US, 2% of women aged 25-34 used long acting reversible contraceptive methods in 1995 compared with 13% of similarly aged women in 2015-17.23 In Europe, 9% of women of reproductive age reported that they used long acting reversible contraceptive methods in 2019.1

Most research on the use of contraceptives and fertility has focused on the effect of oral contraceptives on fecundability; the average probability of pregnancy during one menstrual cycle for a couple engaging in regular intercourse without contraception. Several studies reported delays of about three months in return of fertility after stopping oral contraceptives.456 In some57 but not all studies,4 women who used oral contraceptives for long periods had greater fecundability than women who used oral contraceptives for shorter periods. Less is known about the association between the use of other methods of contraception and fertility, however. Recent use of intrauterine devices (copper and hormonal methods combined) was associated with a slightly longer time to conception than use of barrier methods.68 The results are conflicting,49 however, and could be confounded by parity or underlying fecundity because previous indicators of fertility could affect the choice of contraceptive and the probability of conception in the future. One study indicated that recent use of injectable contraceptives might be associated with delayed conception.4 Most studies examining less common contraceptive methods have been small489 or retrospective in design, with a risk of recall bias.68 Given the increasing popularity of long acting reversible contraceptive methods and other alternatives to oral contraceptives, more research into their short and long term effects on fertility is needed.

This investigation was designed to examine fecundability in relation to recency and length of use of various hormonal and non-hormonal contraceptive methods, in three large preconception cohorts. The cohorts were from three prospective studies from North America and Denmark of women and men planning pregnancies.

We pooled data from three prospective cohort studies of participants planning pregnancies: Snart Gravid, a Danish study of women planning pregnancies, aged 18-49 (2007-11); Snart Foraeldre, an extension of Snart Gravid that included male partners (2011-19); and Pregnancy Study Online (PRESTO), a North American study of women planning pregnancies, aged 21-45, and their male partners (2013-19). Recruitment for Snart Foraeldre and PRESTO is ongoing. Participants in all studies were recruited mainly by advertisements on social media and health related websites, such as Facebook and Netdoktor (www.netdoktor.dk, a well known Danish health related website).1011 For example, we used the following advertisement on Facebook to recruit participants for PRESTO: Trying to conceive? Help scientists learn more about fertility. Enroll in an online research study. The recruitment methods for the study have been described in detail elsewhere.101112

Enrollment and primary data collection were done by email and through the study website. Eligible women were not pregnant, did not use contraceptives, were not receiving fertility treatment, and were trying to conceive. We excluded participants if they reported insufficient or implausible information on their menstrual cycle (Snart Gravid 5%, Snart Foraeldre 8%, PRESTO 2%). We also excluded participants who had been trying to conceive for more than six menstrual cycles at study entry; excluding these participants reduced potential recall bias (that is, differential recall and reporting of exposures and covariates resulting from reduced fertility) and possible confounder misclassification, which might arise if women who had been trying to conceive for longer than six cycles changed their behavior as a result of not conceiving before entering the study. The proportions of women excluded because they had been trying to conceive for more than six cycles were 22% in Snart Gravid, 25% in Snart Foraeldre, and 20% in PRESTO. Participants whose last method of contraception was not included in the present analysis (sterilization that was subsequently reversed, emergency contraception, and douching) were also excluded (<1% of participants). A total of 17954 participants were included in the pooled analyses: 4435 from the Snart Gravid study, 4768 from the Snart Foraeldre study, and 8751 from PRESTO (fig 1).

Flowchart of enrolment and exclusions in the Snart Gravid, Snart Foraeldre, and PRESTO studies (n=17954), 2007-19

All questionnaires were completed online. At baseline, participants reported exposure and covariate information, including personal characteristics, lifestyle factors, and medical history. Follow-up questionnaires were done every two months for 12 months or until a pregnancy was reported, whichever came first. More than 80% of participants completed at least one follow-up questionnaire.All participants provided online informed consent.

At baseline, participants reported the contraceptive method used most recently before they tried to conceive (Which birth control method did you use most recently?). Categories included barrier methods (condoms, diaphragm, sponge, foam (Snart Gravid and Snart Foraeldre studies only), jellies, creams, and suppositories), oral contraceptives (progestin only and combined), hormonal intrauterine devices, copper intrauterine devices, patches, injectable contraceptives, vaginal rings, implants, and natural methods (withdrawal, avoiding sex when fertile, calendar methods, and monitoring cervical mucus or basal body temperature). Those who used hormonal methods recently were asked if they waited for a period of time after stopping hormonal contraception before trying to conceive (Did you wait a few months after stopping hormonal contraception before trying to get pregnant? If yes, For how many months did you wait between stopping hormonal contraception and trying to get pregnant?).

To evaluate the potential effects of recent use of hormonal contraceptives, participants who reported waiting longer than one month before trying to conceive after stopping hormonal contraception were categorized as users of barrier or natural methods based on their questionnaire responses. Participants in the Snart Foraeldre and Snart Gravid studies selected only one most recent contraceptive method, but participants in PRESTO could select more than one method. Those who reported that they used both hormonal and barrier methods were categorized as users of the hormonal method, and those who reported that they used both barrier and natural methods were categorized as users of barrier methods. Participants who selected more than one hormonal method were categorized based on their reported ages when they stopped.

In PRESTO, participants reported the total number of hormonal contraceptive types they had used in their lifetime (oral contraceptives, rings, implants, injectable contraceptives, patches, hormonal intrauterine devices), the name of each method, and their ages when they started and stopped each method. Length of use (years) was calculated separately for each type of hormonal contraceptive. In the Snart Gravid and Snart Foraeldre studies, a detailed history of length of use was collected only for oral contraceptives.

We collected data on menstrual cycle dates and pregnancy status from the baseline and follow-up questionnaires. At baseline, participants reported the typical length of their menstrual cycle, the date of their last menstrual period, and the number of menstrual periods they had since they began trying to conceive. At each follow-up, women reported the date of their last menstrual period, whether they were pregnant, and whether they had started fertility treatment. In the PRESTO cohort, we also identified pregnancies in participants lost to follow-up by linking to birth registries, searching for baby gift registries and birth announcements online, and contacting the participants directly. We calculated pregnancy attempt time, rounded to the nearest whole cycle, as: (number of menstrual cycles participants had been trying to conceive at baseline)+[(date of last menstrual period from most recent follow-up questionnairedate of baseline questionnaire)/cycle length]+1.

At baseline, participants reported their age, height, weight, smoking history, education, household income, and frequency of intercourse; length of their relationship; whether they were trying to improve the chances of conception (eg, timing intercourse to their fertile period); length of the menstrual cycle and regularity; parity; history of infertility (previously tried to conceive for 12 months); history of physician diagnosed endometriosis, uterine leiomyomata, polycystic ovarian syndrome, or type 2 diabetes; and whether they had ever been pregnant, the outcome of each pregnancy (miscarriage, induced abortion, livebirth), and whether the pregnancy had been planned. We calculated body mass index. In PRESTO, participants also reported their race and ethnicity at baseline. Education and household income were determined differently in the Danish and North American cohorts. To pool the data, we developed similar categories for each cohort by dichotomizing household income at $50000 (Danish Kr313 845; 38 250; 42 172) per year for the PRESTO cohort and Kr300000 (6092; $7963; 6717) per year for the Snart Foraeldre and Snart Gravid studies. Education was reported as years of education after compulsory schooling in the Snart Foraeldre and Snart Gravid studies and as overall years of schooling in PRESTO, and categorized accordingly.

Women contributed at risk cycles to the analysis from study entry until they reported a pregnancy, started fertility treatment, withdrew from the study, stopped trying to conceive, were lost to follow-up, or had 12 cycles of trying to conceive, whichever occurred first. We used life table methods to calculate the percentage of couples who conceived during six and 12 cycles of follow-up, accounting for censoring events.13 We used proportional probability regression models to calculate fecundability ratios with 95% confidence intervals.14 The fecundability ratio is a measure of the average probability of conception per cycle comparing users of a specific contraceptive method with a reference group. Proportional probability models adjust for cycle at risk, taking into account the average decline in fecundability as fertile couples conceive and are removed from the population at risk over time.14 We used the Andersen-Gill data structure to account for left truncation bias that might result from women entering the study after at least one cycle of trying to conceive.1516 For example, participants that entered the study after one cycle of trying to conceive, and conceived during the fifth cycle, contributed cycles two to five to the analysis.

We first examined the association between fecundabilitythe probability of conception per cycleand use of oral contraceptives (combined and progestin only), hormonal intrauterine devices, copper intrauterine devices, rings, implants, patches, injectable contraceptives, and natural methods as the last method of contraception compared with barrier methods. We selected barrier methods as the reference group because: use of barrier methods would not be expected to cause changes in the vaginal environment or hormone concentrations, offering a well defined contrast with the use of hormonal methods; a large proportion of couples in our study used barrier methods; and we could compare our findings with previous studies that used the same reference category. We then examined fecundability after the use of hormonal intrauterine devices compared with copper intrauterine devices. To quantify delay in return of fertility for each method of contraception, we examined fecundability in each menstrual cycle when participants were trying to conceive. We considered the return of fertility to occur during the cycle in which fecundability for users of a specific method was not meaningfully lower than that for users of barrier methods (that is, adjusted fecundability ratio >0.90). Lastly, we examined the total length of use of each hormonal method. Total length of contraceptive use was divided into two year categories and compared with less than two years of use. In the Snart Foraeldre and Snart Gravid studies, this analysis was conducted only for oral contraceptives because of limited data on length of use.

Models were adjusted for potential confounders measured in the three studies and selected a priori based on the literature and a directed acyclic graph. Potential confounders included cohort (Snart Gravid, Snart Foraeldre, PRESTO); age (<25, 25-29, 30-34, 35); education (12, 13-15, 16, or 17 years in North America or fundamental education, technical education or less than three years of higher education, three to four years of higher education, or greater than four years of higher education in Denmark); non-Hispanic white race and ethnicity (yes v no); household income (

We also considered adjustment for possible indicators of underlying fertility because women with a previous pregnancy might be more likely to use a long acting reversible contraceptive method to avoid pregnancy if they believe it is more effective. Also, women with reproductive disorders associated with infertility might make contraceptive choices based on treatment recommendations (eg, use of oral contraceptives to treat polycystic ovarian syndrome17). In this analysis, we adjusted for history of unplanned pregnancy (yes v no); history of induced abortion (yes v no); history of infertility (yes v no); menstrual cycle characteristics (irregular cycles, regular cycles of <26 days, regular cycles of 2630 days, and regular cycles of 31 days); parity (parous v nulliparous); and physician diagnosed endometriosis (yes v no), uterine leiomyomata (yes v no), or polycystic ovarian syndrome (yes v no). To examine effect measure modification, results for the most recent type of contraception were examined separately by cohort (Denmark v North America), age (<30 v 30), attempt time at study entry (<3 v 3-6 menstrual cycles), body mass index (<30 v 30), history of infertility (yes v no), parity (parous v nulliparous), and menstrual cycle regularity (regular v irregular).

We conducted two sensitivity analyses to evaluate potential bias as a result of misclassification of exposure. We excluded women who stopped hormonal methods of contraception for one or more months before trying to conceive. These women could have switched from hormonal to barrier methods because of concerns that it would take time for the menstrual cycle to normalize after using hormonal contraceptives. Also, we separated progestin only from combined oral contraceptives to consider the potential extent of bias because of analyzing all oral contraceptives in one group. We conducted this analysis in the PRESTO cohort and evaluated the proportion of women who used progestin only oral contraceptives. We also examined the association between recent use of oral contraceptives and fecundability for progestin only and combined oral contraceptives separately.

In each cohort, we used PROC MI to impute missing exposure and covariate values, with over 100 variables in the imputation model to create five datasets. Last method of contraception was imputed for 0.7% of participants in PRESTO and for 0.5% of participants in the Snart Foraeldre and Snart Gravid studies. We also imputed missing outcome data for participants who did not complete any follow-up questionnaires (16% in PRESTO and 13% in Snart Gravid and Snart Foraeldre) to minimize potential selection bias. We assigned these participants one cycle of follow-up and imputed their pregnancy status (pregnant v not pregnant) for that cycle. We used PROC MIANALYZE to combine coefficient and standard error estimates across imputed datasets.18

No patients were involved in developing the research question, study design, or outcome measures, or in the implementation of this study.

Overall, 17954 women contributed a total of 10729 pregnancies during 66759 menstrual cycles of observation to the analysis. With life table methods, about 56% and 77% of women conceived within six and 12 cycles of follow-up, respectively. After recategorizing participants who reported waiting longer than one month after stopping hormonal contraception, the most commonly reported last method of contraception was oral contraceptives (37.5%), followed by barrier (30.6%) and natural (15.4%) methods (table 1). About 13.3% of women used long acting reversible contraceptive methods, and the most frequently used were intrauterine devices: 7.8% of women used the hormonal intrauterine device and 4.0% of women used the copper intrauterine device as their last method of contraception. The average number of pregnancy attempts before study entry was similar for all contraceptive methods (two menstrual cycles). Users of injectable contraceptives had a higher body mass index on average and were more likely to be current smokers, to report a history of infertility, to have irregular menstrual cycles, and to have type 2 diabetes than users of all other methods of contraception, but were less likely to report trying to improve their chances of conceiving. On average, users of implant, patch, and injectable contraceptives reported fewer years of education and lower household income than users of other methods. Users of intrauterine devices were more likely to be parous and to report a history of unplanned pregnancy than users of other contraceptive methods.

Baseline characteristics of participants planning pregnancies by last method of contraception in the Snart Gravid, Snart Foraeldre, and PRESTO studies (n=17954), 2007-19

Use of injectable contraceptives as the last method of contraception was associated with decreased fecundability compared with use of barrier methods (fecundability ratio 0.65, 95% confidence interval 0.47 to 0.89) after adjusting for personal factors, lifestyle characteristics, and medical history (table 2). This association remained after further adjustment for indicators of underlying fertility (fecundability ratio 0.65, 95% confidence interval 0.47 to 0.89). Users of hormonal intrauterine devices had an increase in fecundability compared with users of barrier methods (fecundability ratio 1.23, 95% confidence interval 1.15 to 1.31) and users of copper intrauterine devices (fecundability ratio 1.19, 95% confidence interval 1.07 to 1.33). These associations were slightly reduced after further adjustment for indicators of underlying fertility. The fully adjusted fecundability ratio was 1.14 (95% confidence interval 1.07 to 1.22) comparing users of hormonal intrauterine devices with users of barrier methods, and 1.18 (95% confidence interval 1.05 to 1.33) comparing users of hormonal intrauterine devices with users of copper intrauterine devices. On average, use of oral contraceptives, copper intrauterine devices, rings, implants, patches, or natural methods as the last method of contraception was not meaningfully associated with fecundability compared with the use of barrier methods as the last method of contraception.

Last method of contraception and fecundability in participants planning pregnancies in the Snart Gravid, Snart Foraeldre, and PRESTO studies (n=17954), 2007-19

Figure 2 and table 3 show the cycle specific probability of conception and fecundability ratios, respectively, for recent users of different methods of contraception. Compared with users of barrier methods, we found varying delays in return of fertility for recent users of alternative methods. On average, users of injectable contraceptives had the longest delay in return of normal fertility (five to eight cycles), followed by users of patch contraceptives (four cycles), users of oral and ring contraceptives (three cycles), and users of hormonal and copper intrauterine devices and implant contraceptives (two cycles) (table 3). Our results were imprecise for these analyses, however. Because of the small numbers of women who used less common methods, we grouped cycles five to eight and nine to 12 for this analysis.

Per cycle probability of conception for common contraceptive methods in the Snart Gravid, Snart Foraeldre, and PRESTO studies (n=17954), 2007-19. Results are shown for barrier methods and the four most common methods of hormonal contraception. IUD=intrauterine device

Last method of contraception and fecundability in participants planning pregnancies by cycle of attempted pregnancy in the Snart Gravid, Snart Foraeldre, and PRESTO studies (n=17954), 2007-19

Overall, associations between last method of contraception and fecundability did not differ widely across cohorts (Denmark v North America), age (<30 v 30), or body mass index (<30 v 30) (table 4). The results varied by the number of menstrual cycles couples had been trying to conceive at study entry, however: relative to barrier methods, use of oral contraceptives, the patch, and injectable contraceptives was associated with decreased fecundability in women who had been trying to conceive for less than three cycles at study entry, but was associated with improved fecundability in women who had been trying to conceive for three to six cycles. This pattern is consistent with a short term delay in return of fertility. Results were similar across groups when we stratified by history of infertility, parity, and regularity of the menstrual cycle (table 4).

Last method of contraception and fecundability in participants planning pregnancies stratified by cohort, age, body mass index, attempt time at study entry, history of infertility, parity, and menstrual cycle regularity in the Snart Gravid, Snart Foraeldre, and PRESTO studies (n=17954), 2007-19

In the PRESTO cohort, no evidence was found of decreased fecundability with longer total lifetime use of oral contraceptives, rings, injectable contraceptives, hormonal intrauterine devices, implants, or patches (eTable 1). In Snart Gravid and Snart Foraeldre, we found a trend of increasing fecundability with longer lifetime use of oral contraceptives. The adjusted fecundability ratio comparing participants who used oral contraceptives for four to five years with those who used oral contraceptives for less than two years was 1.20 (95% confidence interval 1.05 to 1.36).

About 18.5% of participants stopped using hormonal methods of contraception and used natural or barrier methods for one or more months before attempting to conceive. The results were consistent when we excluded these women from the main analyses (eTable 2). In PRESTO, about 3.7% of women reported ever having used a progestin only oral contraceptive, and 1.0% of women (n=89) used the progestin only oral contraceptive as their last method of contraception. The adjusted fecundability ratio comparing users of a progestin only oral contraceptive with users of barrier methods was 1.09 (95% confidence interval 0.87 to 1.37). Excluding users of progestin only oral contraceptives from the main analyses did not change our results substantially. The adjusted fecundability ratio comparing users of combined oral contraceptives with users of barrier methods was 0.99 (95% confidence interval 0.92 to 1.07).

In this large prospective cohort study of couples planning pregnancies and residing in Denmark, Canada, and the US, users of oral contraceptives and some long acting reversible contraceptive methods experienced short term delays in return of fertility compared with users of barrier methods. On average, users of injectable contraceptives had the longest delay in return of normal fertility whereas users of hormonal intrauterine devices, copper intrauterine devices, and implant contraceptives had the shortest delays. Long term use of these methods did not appear to be detrimental to fertility. About 13% of women reported that they used a long acting reversible contraceptive as their last method of contraception, which is consistent with previous descriptions of use of long acting reversible contraceptives in the US.23 Our findings for use of barrier methods were also consistent with previous studies that reported that 28% of women in the US of reproductive age who are cohabiting, engaged, or married use condoms.19

The delay in return of fertility that we found was consistent with our previous study examining the use of oral contraceptives in a subset of the present Snart Gravid cohort.5 Our results were also consistent with several studies that reported slight delays in return of fertility after use of oral contraceptives,6 intrauterine devices,68 and implants,4 and longer delays after use of injectable contraceptives.420 We found little association between length of use and fecundability in the PRESTO cohort, but improved fecundability after long term use of oral contraceptives in the Snart Gravid and Snart Foraeldre studies. Our finding in the Snart Gravid and Snart Foraeldre studies is consistent with a retrospective study conducted in 8497 pregnant women in southwest England.7 This higher fecundability has been attributed to the prevention of ovulation that occurs with use of oral contraceptives,21 which might help to maintain ovarian reserve.2223 Research on this question has shown inconsistent results, however, and potential mechanisms (eg, reduced rates of atresia) have not been fully explained.24252627

Recent use of hormonal contraceptives could influence the return of fecundability by several mechanisms. Combined oral contraceptives contain estrogen and progestin, which block the normal release of gonadotropin releasing hormone by the hypothalamus, suppressing production of follicle stimulating hormone and luteinizing hormone, and ultimately suppressing ovulation.21 Although oral contraceptives have a short half-life, prevention of ovulation, changes in cervical mucus, and thinning of the endometrium could persist after stopping oral contraceptives. The vaginal ring and transdermal patch act by a similar mechanism2829 and might continue to suppress ovarian function immediately after stopping use of these contraceptives.30 Progestin only injectable, implant, and oral contraceptives also act at the pituitary and hypothalamic levels to suppress ovulation and have effects on cervical mucus and endometrial thickness.21 Also, injectable contraceptives contain substantially higher dosages of progestin than other contraceptive methods as they are designed to prevent pregnancy for at least 90 days after injection.3132 The most common type of injectable contraceptive is depot medroxyprogesterone acetate (DMPA), which is given intramuscularly in a 150 mg dose and has a half-life of 50 days. Levels of DMPA are detectable (<100 pg/mL) for 120-200 days after injection.33 The longer half-life of DMPA could explain the overall reduced fecundability and longer delay in return of fertility in users of injectable contraceptives. Our findings also agree with a previous study that reported a threefold longer time to pregnancy for users of injectable contraceptives than users of condoms after stopping contraception.4 The characteristics of users of injectable contraceptives differed from those of users of barrier method in our study, however. Residual confounding by unmeasured factors, such as overall health condition and knowledge of reproductive health, might explain part of the association seen.

The average per cycle probability of conception was about 20% higher in women who used the hormonal intrauterine device than in those who used barrier methods. We expected that women with proven fertility (that is, women with previous pregnancies) would be more likely to use intrauterine devices and to have greater fecundability than women who used barrier methods. Although users of intrauterine devices were more likely to be parous than users of other methods, adjustment for parity and other indicators of underlying fertility did not explain our findings. Also, the fecundability ratio comparing users of hormonal intrauterine devices with users of barrier methods (1.14; 95% confidence interval 1.07 to 1.22) was similar to the fecundability ratio comparing users of hormonal intrauterine devices with users of copper intrauterine devices (1.18; 95% confidence interval 1.05 to 1.33). This finding suggests that users of hormonal intrauterine devices have improved fecundability relative to users of barrier methods and copper intrauterine devices, and that this effect is not confounded by underlying fertility.

Hormonal intrauterine devices release levonorgestrel, a progestin that creates a spermicidal environment and prevents fertilization or implantation. Unlike other hormonal methods, the hormonal intrauterine device does not suppress ovulation.34 Similarly, the copper intrauterine device prevents fertilization and implantation but has no effect on ovulation. The mechanisms by which copper intrauterine devices prevent pregnancy are not fully understood, however. Most research on intrauterine devices and fecundability has not examined intrauterine devices separately by type,689 with the exception of one randomized trial conducted in 1993.35 In the randomized trial, the investigators evaluated fecundability after removal of the intrauterine device and found slightly higher pregnancy rates in women assigned to the levonorgestrel intrauterine device compared with the copper intrauterine device.

This study had several limitations. First, some misclassification of cycles was likely because our calculation of time-to-pregnancy relied on reported length of the menstrual cycle36 and date of the last menstrual period.11 Misclassification could also have arisen if participants interpreted the question, Did you wait a few months after stopping hormonal contraception before trying to get pregnant? as asking about two or three months specifically. The extent of misclassification is likely to be small, however, because 45% of participants who reported waiting indicated that they waited more than three months, and 16% reported having waited less than 2 months. Second, confidence intervals were wide in the analyses of less commonly used contraceptive methods, limiting our ability to identify the timing of return of fertility. Third, we did not collect data on the date of the last injection for women who used injectable contraceptives. This lack of data limited our ability to determine the recency of use in women who used injectable contraceptives continuously and to evaluate potential misclassification of wait time in women who reported stopping injectable contraceptives a few months before trying to conceive.

In this study, two potential sources of selection bias were identified. Study cohorts were based on self-selection and were volunteers. Women who volunteer to participate in research might differ from those who decline. We believe that our findings are internally valid and externally applicable to those planning pregnancies, however, because the physiological mechanisms underlying the effects that we examined are unlikely to vary substantially between women who did and did not participate. Also, women who conceive immediately after stopping contraception might be less likely to enroll in the study. About 50% of study participants reported that the number of attempts at conceiving was less than two menstrual cycles at study entry, however. This finding indicates that we were successful in recruiting couples at the beginning of their attempts to conceive. We also found minimal evidence of bias in a previous empirical evaluation of the potential for selection bias in Snart Gravid.37 Overall, we expect any potential selection bias to be minimal.

For our analysis of length of use, two limitations were identified. Precision was limited because a detailed history of use of all types of hormonal contraceptives was available only for participants in PRESTO. Also, reporting of contraceptive methods is likely to be less accurate for methods used in the distant past than those used recently. Given the prospective cohort design, any errors in recall of contraception are expected to be unrelated to outcome, leading to reduced associations for extreme categories of length of contraception use.

In this large prospective investigation, we examined the association between pregravid use of contraceptives and subsequent fecundability. We considered several less studied long acting reversible contraceptive methods, including implants and injectable contraceptives, and also individual intrauterine device types. Our findings suggested that return of normal fertility varies substantially by contraceptive method. Overall, we found that use of intrauterine devices and implant contraceptives was associated with short delays in the return of fertility, with injectable contraceptives showing the longest delay (about five to eight menstrual cycles). Our results, although imprecise, indicate little or no lasting effect of long term use of these methods on fecundability. As the use of long acting reversible contraceptive methods becomes more common worldwide, these findings might inform clinical recommendations on contraceptive decision making. Understanding the comparative effects of different contraceptives on fecundity is essential for family planning, counselling for contraception, and management of infertility.

Use of long acting reversible contraceptives has become increasingly common but epidemiologic studies of their effect on return of fertility have been small and inconsistent

Research on use of contraceptives and fertility has focused mainly on the effects of oral contraceptives, with most studies showing short delays in the return of fertility after stopping oral contraceptives

This study quantified the delay in return of fertility after use of a variety of contraceptive methods

On average, users of injectable contraceptives had the longest delay in return of normal fertility (five to eight menstrual cycles) and users of hormonal and copper intrauterine devices and implant contraceptives had the shortest delays (two menstrual cycles)

Read the original:
Pregravid contraceptive use and fecundability: prospective cohort study - The BMJ

Recommendation and review posted by Bethany Smith

16 November 2020

Organoids can be used to study early stages of heart development in mouse embryos, a new study shows.

Researchers from the cole Polytechnique Fdrale de Lausanne, Switzerland, have reported that they were able to produce a mouse heart organoid from embryonic stem cells, which displayed essential features of an early developing heart. They suggested that this reveals a novel application of organoids for studying early embryonic stages of development.

'One of the advantages of embryonic organoids is that, through the co-development of multiple tissues, they preserve crucial interactions that are necessary for embryonic organogenesis,' said Dr Giuliana Rossi, lead author of the study. 'The emerging cardiac cells are thus exposed to a context similar to the one that they encounter in the embryo.'

In their study, published in Cell Stem Cell, the team exposed mouse embryonic stem cells to a mix of three factors involved in promoting heart growth. One week later, the stem cells self-organised into so-called gastruloids:organoids with an embryo-like organisation, which displayed signs of early heart development. The cell aggregatesnot only expressed several genes known to regulate cardiovascular development, but also generated a structure resembling a vascular network. Furthermore, the researchers found an 'anterior cardiac crescent-like domain' in the gastruloids, which even produced a beating heart tissue. Similar to the muscle cells of the embryonic heart, this area was also sensitive to calcium ions.

Organoids have been mostly the focus of research into the generation of adult tissues and organs for pharmaceutical and medical research. In their new publication, Professor Matthias Ltolf and his team suggested that they can also provide a system to study early embryonic stages of the developing heart and other organs, as they preserve important tissue-tissue interactions.

Visit link:
Organoids mimic the early development of the heart in mouse embryos - BioNews

Recommendation and review posted by Bethany Smith

Once upon a time, growing organs in the lab were science fiction. But now, methods such as stem cell biology and tissue engineering have turned that fiction into reality with the advent of organoids.

Organoids are tiny lab-grown tissues and organs that are anatomically correct and physiologically functional.

Recently, the lab of Matthias Ltolf at the School of Life Sciences at EPFL has successfully produced a mouse heart organoid in its early embryonic stages. Scientists grew organoids from mouse embryonic stem cells, which, under the right conditions, can self-organize into structures that mimic aspects of the architecture, cellular composition, and function of tissues found in real organs.

Placed in cell-culture under specific conditions, the embryonic stem cells from a three-dimensional aggregate called a gastruloid, which can follow the mouse embryos developmental phases.

This studys idea was that the mouse gastruloid could be utilized to mimic the beginning phases of heart development in the embryo. This is a new use of organoids, which are commonly developed to mimic adult tissues and organs.

Also, there are three features of mouse gastruloids that make them a suitable template for mimicking embryonic development: they establish a body plan like real embryos. They show similar gene expression patterns. And when it comes to the heart, which is the first organ to form and function in the embryo, the mouse gastruloid also preserves important tissue-tissue interactions necessary to grow one.

Equipped with this, the scientists exposed mouse embryonic stem cells to a cocktail of three factors known to promote heart growth. Following 168 hours, the subsequent gastruloids gave early heart development indications: they expressed several genes that regulate cardiovascular development in the embryo. They even generated what resembled a vascular network.

Importantly, scientists found that the gastruloids developed what they call an anterior cardiac crescent-like domain. This structure produced a beating heart tissue, similar to the embryonic heart. As the muscle cells of the embryonic heart, the beating compartment was also sensitive to calcium ions.

Giuliana Rossi, a post-doctoral researcher from Ltolfs laboratory, said,Opening up an entirely new dimension to organoids, the breakthrough work shows they can also be used to mimic embryonic stages of development. One of the advantages of embryonic organoids is that, through the co-development of multiple tissues, they preserve crucial interactions that are necessary for embryonic organogenesis.

The emerging cardiac cells are thus exposed to a context similar to the one that they encounter in the embryo.

The study was conducted in collaboration with Viventis Microscopy, EPFL Bioimaging and Optics Platform, Institut de Biologie du Dveloppement de Marseille, Johns Hopkins University School of Medicine, EPFL Institute of Chemical Sciences and Engineering.

Read more:
Mimicking the early development of the heart - Tech Explorist

Recommendation and review posted by Bethany Smith

DUBLIN--(BUSINESS WIRE)--The "Cell Therapy and Gene Therapy Markets" report has been added to ResearchAndMarkets.com's offering.

This is an exciting and interesting time in the cell and gene therapy industry. The science is moving ahead as industry industrializes and standardizes the manufacturing and commercialization of products. Cell and gene therapy products are transforming the treatment of cancers and genetic diseases, as well as expanding into other areas of medicine including autoimmune diseases, cardiovascular diseases, musculoskeletal disease, dermatological diseases, and many others.

Cell Therapy and Gene Therapy Markets presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.

The following conditions/disorders are covered:

Dermatology, including:

Oncology, including:

Ophthalmic Conditions, including:

Other Conditions, including:

The report comments on the current COVID-19 cell and gene therapy pipeline. There are a number of companies that are responding to the call to develop a therapeutic or vaccine for the coronavirus, including:

The leading influencers in the market are those which have become first-to-market participants in the cell and gene therapy segment, have new developments which may disrupt current market conditions, and/or have an extensive pipeline sure to impact the market in the long-term forecast:

Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2019 and the expected market for 2020 based on first-quarter company reports and are expressed in current dollars. Forecasts are provided through 2025 and an extended forecast for 2030. The size of each market segment refers to manufacturers' revenues.

For more information about this report visit https://www.researchandmarkets.com/r/ek1qqb

See original here:
Cell Therapy and Gene Therapy Markets, 2019-2020 & Forecast to 2025 and 2030 - ResearchAndMarkets.com - Business Wire

Recommendation and review posted by Bethany Smith

Another day, another win for Mercks blockbuster Keytruda.

The FDA has granted accelerated approval for the cash cow combined with chemotherapy in triple negative breast cancer, giving the drug the green light in its 18th different cancer. Mondays new indication comes for patients with PD-L1-expressing tumors with a Combined Positive Score of at least 10.

Merck noted that due to the nature of the accelerated approval, the thumbs up is contingent upon confirmatory trials.

Data for the approval first came back in February, when the Keynote-355 trial demonstrated Keytruda plus chemo significantly improved progression-free survival compared to chemo by itself. The study showed that, in the target population with a CPS of at least 10, the combination reduced the risk of disease progression or death by 35% with a median PFS of 9.7 months, against 5.6 months in the placebo arm.

On safety, the February data showed 2.5% of all patients in the drug arm saw fatal adverse events, including cardiac arrest and septic shock, with serious side effects appearing in 30% of patients. Keytruda was discontinued due to adverse events in 11% of patients.

Frontline triple negative breast cancer is a particularly difficult indication to treat, as the growth of the cancer is not fueled by the hormones estrogen and progesterone, or by the HER2 protein. Its one of the rare fields in which Roches PD-L1 Tecentriq has enjoyed a head start over Keytruda and Opdivo, the leaders in the checkpoint race, as Tecentriq is approved in combination with Abraxane for this indication.

Back in May 2019, Merck conceded a failure in the arena after a Phase III study flopped on overall survival. But a few months later, the pharma turned things around after discovering a neoadjuvant regimen of Keytruda and chemo followed by Keytruda monotherapy after surgery induced a higher pathological complete response rate.

Though execs presented that as a positive, some analysts didnt paint as sunny a picture. This past February, when the Keynote-355 topline data was first published, SVB Leerinks Daina Graybosch pointed out that because only patients with a CPS of at least 10 appeared to benefit, instead of a score of at least 1, it wont be able to treat as broad a population as Tecentriq. Roche, she noted, also has about a two-year head start.

A Merck spokesperson also had this to say about the CPS and IC percentages:

In TNBC, we measure PD-L1 with a combined positive score (CPS). The CPS includes staining for tumor cells, as well as tumor-infiltrating immune cells and it is not a percentage. We believe CPS 10 is roughly equivalent to how Roche scores PD-L1+ patients (IC>=1% based on the SP142 assay) on tumor-infiltrating immune cells (IC). The prevalence of the PD-L1 positive population in TNBC whether by CPS of greater than or equal to 10 or IC of 1% is both about 40%.

Keytruda is already one of the best-selling drugs in the world, having notched roughly $3.9 billion in the first half of 2020 alone. Some have predicted the drug may overtake AbbVies Humira as the top seller within the next few years, with the most optimistic estimate pegged for $22.2 billion in sales by 2025.

Follow this link:
UPDATED: Merck's Keytruda nets another approval, this time in triple negative breast cancer. Can it catch up to Tecentriq? - Endpoints News

Recommendation and review posted by Bethany Smith

Crom Rehabilitation puts your physical therapy goals first while striving to keep you safe.

Here in the U.S. and around the globe, were struggling to get used to the new normal, at least for the time being. Really, none of us have ever been through anything like this! Itll be wonderful when COVID is under control but until then, we must all do our part to keep others safe.

Crom Rehabilitation is built on the principle of putting you and your physical therapy goals first but we also need to keep you safe and do as much as we possibly can to avoid spreading this terrible virus while youre visiting our center! When you come into the Crom Rehabilitation Houston clinic, your time and resources will be respected as our professional staff works to create a rehabilitative program that is tailored to meet your needs and help you effectively achieve your therapeutic goals. Together with our team of experienced therapists, we will work towards helping you reach your maximum rehabilitative potential and return to your previous lifestyle without pain or disability.

Our profession has gained some regulatory momentum.Heres some food for thought: our profession has fought hard to get to the level of autonomy and recognition we have garnered this far. The fact that physical therapy has been recognized at the federal level as essential work is monumental. We now have an opportunity to shine and truly show that we have the skills, education, and fortitude to be considered primary care providers for neuromusculoskeletal issues. What better use of our skillset than to assist in this time of crisis in order to reduce the volume of musculoskeletal pain patients in emergency rooms and urgent care? We are trained in use of personal protective equipment (PPE); we understand the science behind viral transmission and can help educate our patients-and their families-on proper handwashing, sanitization, and other ways to mitigate infection.

When we first started hearing about COVID-19 (coronavirus) in the media, it seemed like the chances of a global pandemic-while possible-were more hypothetical than anything. After all, we have seen other health concerns rise and recede-but this part of the world, we have experienced little social impact. And now, here we are almost overnight, it seems we have found ourselves in the middle of a global crisis. And while solutions are in flight, it will probably be some time before things fully return to normal-whatever the new normal may be.

Embrace social distancing.According to the CDC, this entire year is going to remain challenging and as much as many of us are tired of the masks, lockdowns etc its very important that we all do our part! In addition to carrying over sanitization best practices from your home to the Crom clinic, you should also follow similar social distancing guidelines. By nature, physical therapy has some unique challenges when it comes to maintaining a healthy distance between patients and providers. However, here are a few best practices that will reduce the risk of unnecessary contact:

Taking Care of Our PatientsConsidering all the business and financial uncertainty, it is vital that physical therapy practice owners do not forget our overarching mission as healthcare providers: ensuring the health and wellbeing of outpatients. Our patients are our most valuable asset, and many of them fall into the high risk category, which means they are even more scared. Plus, they are hearing all kinds of information, statistics and hypotheticals from people who may, or many are not trusted sources. As their physical therapist, you play the role of care provider, educator, and-now more than ever-a guiding light in the storm ahead.

Taking Care of YourselfThe most important part of this entire crisis is you! This may seem oversimplified, but your first line of defense starts at home. I suspect this wont be news to any of you, but keeping your home environment clean is the key to ensuring you and your family remain healthy as well as slowing the spread of illness, so:

And of course, consume plenty of fresh fruits and vegetables. Chances are that your local grocery store is fully stocked with both at the moment.

There has also been a lot of discussion regarding social distancing, or physical distancing, as the World Health Organization now refers to it, which you should practice at all times. Stick to critical gatherings only and limit them to 10 people or fewer. When you have to leave your home, keep about six feet of distance between you and other people.

Of course, taking care of yourself goes beyond cleanliness and proximity, which is why aggressive hand washing and sanitizing isnt the only thing you should be doing for yourself.

Practice self-careOne of the things that makes this health crisis so unique is that it is not isolated to a single continent or hemisphere-it is everywhere. As a result, the entire world is feeling the effects-both physically and mentally. In moments of stress-and when we experience feelings of helplessness-our brains become flooded with cortisol (the stress hormone) which has been proven to impair brain function, decision-making abilities, and rationalization. For that reason, it is not uncommon for people to turn to unhealthy coping mechanisms. But, as Im sure you know, unhealthy habits can weaken the bodys immunity and when were stressed, our immunity is already less than optimal.

For that reason, it is important to be kind to yourself: go for a walk; meditate; do a quick yoga routine; play with your dog. There are companies that offer extended free trials in light of this crisis (guided meditation apps). And if you find yourself with extra time on your hands, pick up a hobby you wouldnt otherwise have time for: learn an instrument; make a new recipe with the kids; put a dent in your reading list. Devoting time to self-care and wellness is crucial to keeping your mind happy, which will make your body happy, too. These self-care reminders have been extremely helpful to many as they are juggling working, home-schooling children and all the other extra stress that has come along with this pandemic.

Crm Rehabilitation734 North Loop, Houston, TX 77009281-729-5130

For more information, visit cromrehab.com

Read more from the original source:
What Happens to A Physical Therapy Clinic during COVID-19? - outsmartmagazine.com

Recommendation and review posted by Bethany Smith

Decades of research has shown that singing individually and in groups is good for you on many levels.

Here, according to science, are 10 key benefits of raising your voice in song.

Singing appears to be a stress-reliever. A 2017 study measured the amount of cortisol, the stress hormone, in participants saliva before and after they sang.

Researchers in that study found that the amount of cortisol was lower after singing, an indication that people felt more relaxed after theyd belted out a tune.

They also found singing reduces stress levels whether the participants were singing in a group or by themselves.

Theres a small catch, though: Cortisol only goes down if youre singing in a place that doesnt make you anxious. A similar 2015 study tested salivary cortisol levels after a singing performance, finding that cortisol levels went up in this scenario.

Theres some evidence that singing may boost your immune system and help you fight off illnesses.

A 2004 study compared the effects of singing with the effects of simply listening to music. In two separate sessions, research subjects either sang or listened to music.

Those who sang showed higher levels of immunoglobulin A, an antibody your body secretes to help you fend off infections. Listening to music (without singing along) reduced stress hormones but didnt stimulate the bodys immune system.

When you sing in a group, whether its a large choir or a smaller group, the act of collective singing causes your body to release endorphins. This hormone can help promote positive feelings, and even change your perception of pain.

A 2012 study found that singing, drumming, and dancing in a group triggers the release of hormones that raise your pain tolerance in ways that just listening to music doesnt.

Researchers note that the feelings of social connection, rather than the music itself, seems to be behind the boost in pain tolerance.

Regular singing may change the way you breathe, even when youre not singing. Researchers in a 2008 study interviewed the spouses of choir members, along with the spouses of people who dont sing.

The researchers found that significantly fewer choir members snored. This led them to recommend regular singing as a potential treatment for snoring.

Studies have also shown that people who play wind instruments also snore less than the general population.

These findings have prompted some experts to suggest that singing and playing wind instruments might be helpful for people with obstructive sleep apnea (OSA).

Because singing involves deep breathing and the controlled use of muscles in the respiratory system, it may be beneficial for certain lung and breathing conditions.

Studies have shown that the breathing techniques used with singing may offer benefits for people with the following conditions:

While singing doesnt treat or cure any of these conditions, you may benefit from gaining strength in your respiratory muscles.

Singing also increases the amount of oxygen in your blood, research shows. In addition to the pulmonary benefits, singers also experience improved mood and a greater sense of social connection.

When you sing together with others, youre likely to feel the same kind of camaraderie and bonding that players on sports teams experience.

In one 2014 study involving 11,258 schoolchildren, researchers found that children in a singing and musical engagement program developed a strong sense of community and social inclusion.

In a 2016 study involving 375 adult participants, researchers found that people who sang together in a group reported a higher sense of wellbeing and meaningful connection than people who sang solo.

One of the neurochemicals released when people feel bonded together is oxytocin, also known as the love hormone.

Spontaneous, improvised singing causes your body to release this feel-good hormone, which may help give you a heightened sense of connectedness and inclusion.

People with Alzheimers disease and other types of dementia experience a gradual loss of memory. Studies have shown that people with these conditions were able to recall song lyrics more easily than other words.

In one singing study by the Alzheimers Foundation, participants said it was nice to be able to remember something.

However, the singers found they remembered more than just the lyrics. For some, singing familiar songs suddenly brought back life memories theyd forgotten, too.

Researchers found that singing songs learned at a younger age caused a spontaneous return of autobiographical details for many people.

Singing in a group doesnt just help you with physical pain; it may also help with the emotional pain you feel after youve lost someone you love.

In a 2019 study conducted among people dealing with grief, researchers found that for those who sang in a choir, depression symptoms didnt get worse over time and their sense of wellbeing remained stable.

In fact, the choir singers felt a gradual improvement in their self-esteem during and after the 12-week study. Those in the control group who didnt participate in the singing intervention didnt report this benefit.

Researchers concluded that group singing may be a good option for people who need additional support during a time of grief.

A 2018 study done in the United Kingdom evaluated 20 people in a singing program known as The Sing Your Heart Out project. The participants included people with mental health conditions, as well as the general public.

Researchers found that the participants reported improvements in their mental health, mood, sense of well-being, and feeling of belonging as a result of these singing workshops.

Decades ago, scientists began researching the effects of singing among people who have a hard time with speech due to a neurological condition.

To date, researchers have found that singing improves the speaking ability for people with:

Singing stimulates multiple areas of the brain at the same time. This may enable people with an impairment in one part of the brain to communicate using other areas of their brain.

Singing can also prolong the sounds in each word, which may make it easier to pronounce them.

Singing also makes it easier to incorporate hand-tapping, a method that can help people maintain speaking rhythms that are otherwise challenging.

Because SARS-CoV-2, the coronavirus that causes COVID-19, is known to spread through respiratory particles, public health officials have cautioned against events where people sing collectively.

Researchers are currently advising organizers to keep rehearsals short, small, and ideally, remote. Larger, longer events are likely to be problematic for now.

Using masks, outdoor venues, and physical distancing may help, but are not a guarantee that the virus causing COVID-19 wont spread when people meet to sing in person.

Research on this relatively new phenomenon is being continually updated.

Go here to see the original:
Benefits of Singing: 10 Ways Singing Boosts Your Health - Healthline

Recommendation and review posted by Bethany Smith

When Supreme Court justice Ruth Bader Ginsburg died in September, many began to lament the potential undoing of a host of human rights milestones. High among them was the federal decision on abortion access.

In 1973, via the landmark Roe v. Wade decision, the Supreme Court ruled that a woman's right to choose an abortion is protected by the Constitution. Earlier this year, in an amicus brief, more than 200 Republican Congress members urged the Supreme Court to reconsider Roe v. Wade. Anti-abortion activists have been setting up legal cases in states such as Louisiana and Mississippi in an effort to have them heard by the Supreme Court. Meanwhile, Illinois lawmakers have promised the state will continue to provide this necessary medical procedure, regardless of any potential decisions that would undo the precedent set by Roe v. Wade.

Before Ginsburg's death, Brigid Leahy, director of public policy for Planned Parenthood of Illinois, and others were already hard at work solidifying protections. "We have been seeing a steady drumbeat of attacks on access to reproductive health care, and attacks on abortion access in particular. These are state-level attacks and they are part of a national strategy to cut off access to abortion," said Leahy.

As part of an effort to combat those attacks, in 2019 Illinois passed the Reproductive Health Act. The point was to ensure any federal decision would not undermine the ability for people to access abortions in Illinois. Now "access to reproductive health care is a fundamental right under Illinois law," Leahy said. The measure affirmed that the state should handle reproductive procedures the same as all other forms of health care. It also required private medical insurance providers that cover maternal health costs to also cover abortion. The state had decided in 2017 abortion would be covered by Medicaid.

The road to care

According to the Illinois Department of Public Health, the number of nonresidents coming to the state for abortions has risen in recent years. Between 2014 and 2018, the percentage grew by more than 90%, up to 5,669 cases in 2018.

Hope Clinic for Women, in Granite City, is near the state's border with Missouri where there is a single abortion clinic left. Hope Clinic is one of the oldest clinics of its kind in the country, founded in 1974. Many early practitioners there were motivated by the desire to prevent the deaths of women, who had limited options for safe abortion before Roe v. Wade, said Alison Dreith, the clinic's current deputy director.

Missouri is one of the states that has passed sweeping restrictions in recent years. As more states make it harder for people to access care, Hope Clinic has provided an increasing number of abortions, Dreith said. In 2017 and the decade prior, the clinic was seeing about 3,000 patients a year, she said. In 2019, the same year the Reproductive Health Act passed, that number was above 5,000. Dreith said the increase was due to the "proactive legislation in Illinois" as well as "restrictive laws also being passed in our neighboring state."

Photo by Julie Lynn

Activists dressed as handmaids observed an Illinois House human services committee meeting in May of 2019 as the Reproductive Health Act was under consideration. The Handmaids Tale is a book by Margaret Atwood, published in 1985, about a dystopian, patriarchal society where fertile women are enslaved as breeders. The book follows the womens attempts to gain their independence. The novel was made into a popular television series on Hulu, with the first episode released in 2017. Handmaid outfits have become common for those demonstrating in support of reproductive health care in recent years.

Along with the increase of clients has come an increase of opposition. "We've seen an insurgence of new protesters coming to our clinic" and the Trump administration has seemingly emboldened them, said Dreith. She said the protesters have physically blocked clients from getting into the clinic. This form of antagonism, while on the rise, is not new. In 1982 a Hope Clinic doctor and his wife were kidnapped by members of an extremist group called the "Army of God."

Dreith said about 65% of patients come from out of state, largely from Missouri. Last year, The New Yorker wrote about Illinois as an "abortion-rights haven." As the article states, it was long before Ginsburg's death that advocates began the fight to codify abortion rights through additional avenues. "Staff from Planned Parenthood offices across the country were holding a strategy session in Chicago on June 27, 2018, when Supreme Court Justice Anthony Kennedy announced his retirement, clearing the way for Trump to appoint Kavanaugh," the article read. One of those people was Brigid Leahy, who told the magazine, "We started looking state by state and asking, where do we need to shore things up." The goal was to ensure "Illinois was as strong on reproductive rights as we could possibly make it," she had said.

Before Roe v. Wade

Abortion is literally ancient history, with evidence of the practice dating back into the pre-modern era. Miscarriages are quite common. One in eight pregnancies end with one, according to some statistics. Some women need an abortion to assist their miscarriage, a medical intervention for a natural process. Regardless of the reason, without legal and safe abortion, women have taken matters into their own hands, using risky self-induced methods or patronizing unregulated and unsanitary providers. "Almost every abortion death and disability could be prevented through sexuality education, use of effective contraception, provision of safe, legal induced abortion and timely care for complications," according to the World Health Organization.

It took an evolution of thought for LuAnn Atkins to see abortion as a human rights issue. Five decades ago, she was one of the first students at Sangamon State University (SSU) now University of Illinois Springfield. Married with two children, she had moved to Springfield in 1966. While at SSU, she earned a degree in "justice and the social order." During that time she was introduced to the women's liberation movement.

Previously, Atkins had earned a college degree in Texas, and had attended the University of Oklahoma where she had been active in campus ministry. While at SSU she took a human sexuality course and read the book Our Bodies, Ourselves. A touchstone of the second wave of feminism and the women's health movement, the book was created "by and for women." First published in 1970, the book was born of cooperative effort. At a women's liberation conference in Boston in 1969, women shared their accounts related to sexuality, pregnancy, childbirth, menopause and other topics largely considered taboo at the time. Some continued to meet and research, and together they published the book which was then distributed at women's centers and regularly taught on liberal college campuses.

Photo courtesy Hope Clinic for Women

Hope Clinic for Women sponsored this billboard on I-55/64, viewable by drivers to Illinois from Missouri.

"It freed me up to think more about my body and how that relates to my total life. And slowly, my values began to evolve," said Atkins. Atkins found out about an organization based in New York City called the Religious Coalition for Abortion Rights (RCAR). The organization still active and now called the Religious Coalition for Reproductive Care began as an "underground network of ministers and rabbis called the Clergy Consultation Service (CCS), formed in 1967, six years before the Roe v. Wade Supreme Court decision legalized abortion in the United States," according to the group's website. RCAR helped women find safe pathways to abortion. Many of those involved were also participants in the civil rights movement. They saw their work for racial justice to be connected to the fight for reproductive health access.

The 1970 book Our Bodies, Ourselves helped many women realize that a lack of adequate and comprehensive reproductive health care was a common problem.

A Methodist, Atkins felt called toward the intersection of faith and women's health. In 1971, she started a chapter of RCAR in Springfield. There were four clergy people who agreed to help counsel women and two volunteers, including herself. Atkins said two OB-GYN doctors in Springfield agreed to refer women to the local RCAR chapter.

At the time, abortion was legal in Kansas City, so women could be referred to seek assistance there. There were also doctors in Chicago who would perform abortions illegally. For later term abortions, some women would fly to New York City. Atkins said there was a couple in western Illinois, a doctor and a nurse practitioner, who would also perform abortions. She said RCAR members would visit providers they referred women to see. "We wanted to make sure that the places we told people about were safe." She would tell the women she counseled, "I'm not here to question you. I'm not here to make sure you're making the right decision. It's up to you. I just want to help you."

In Springfield, local women had founded the city's first birth control center in 1938. According to the Sangamon County Historical Society, the dominating presence of what is now St. John's Hospital meant doctors were largely averse to assisting the effort, as the Catholic health provider opposed all forms of "unnatural" birth control. Volunteers largely ran the clinic, and it went through a series of iterations and names before becoming officially affiliated with Planned Parenthood in the '70s.

Atkins became the executive director in 1973 and held the post until 1980. Her leadership came on the heels of the Roe v. Wade decision. Atkins went on to work in public health before retiring from St. John's hospice program as a social worker in 1997.

While religious leaders and people of faith, such as Atkins, have long been a part of the battle for women's health care access, it's the so-called religious right that is often given the biggest spotlight in the enduring national debate. Organizations such as the Eagle Forum and the Illinois Family Institute continue to lobby against abortion access, arguing that life begins at conception and embryos and fetuses should be protected by the state.

Photo courtesy UIS Archives

LuAnn Atkins addressed the crowd at an SSU honor dinner. This photo first appeared in the fall, 1975 edition of the universitys magazine. The magazine also had an article in it by Atkins where she wrote about how her experience taking a human sexuality course put her on a path to leading the local Planned Parenthood.

In 2017, at the age of 85, Atkins joined others in Springfield as they rallied to defend funding for Planned Parenthood, squaring off against protesters on the other side of the argument. Dressed in pink, her curly white hair under a floral visor, she held a sign that read, "I will not go quietly back to the 1950s."

"I have been very upset, frankly, over the last 15 or 20 years, that there's been a blurring of the lines between how church and state are separated," she said. "We are not a religious state. We are secular." Abortion access means lower mortality rates for women and bodily autonomy, said Atkins. She said of her ideological opponents, "I don't think it's about saving the fetus. It's about controlling women."

Onward

Jenna Gordon is a social worker with Planned Parenthood of Illinois who works downstate. Like Atkins, she said her role is not to tell clients what to do, but to let them know their options, and support their decisions. She counsels clients from a variety of backgrounds. "I'm typically able to help them with some things such as intimate partner violence, sexual assault or financial and familial strain." When it comes to the decision of how to handle a pregnancy, the approach is that the decision must be up to the patient, "in consultation with their health care provider," she said.

"No matter their reason, we want to be there to help and support them, and we always trust our patients to be making their own fully informed sexual and reproductive health care decisions." Planned Parenthood provides sexually transmitted infection screening and treatment, contraception, gender affirming hormone treatment and other services.

Photo courtesy state Rep. Ann Williams

Women dressed as handmaids, a reference to The Handmaid's Tale, to support passage of the Reproductive Health Act in Illinois and rallied at the Capitol in 2019.

When it comes to abortion, many clients still feel the harmful effects of stigma, said Gordon. "Plenty of my patients tell me about the fact that their family or their partner is going to ostracize them or leave them because of their decision to have an abortion," she said. "It is definitely a misconception that people making decisions regarding their abortions do so in a flippant manner. The reality is that most people are putting deep thought and consideration into their decision." She said even though it can be a heavy choice to make, the most common reaction she hears from clients after the procedures is that of relief.

Planned Parenthood of Illinois continues to push for better access and education throughout the state. While Illinois has become a beacon of access, Brigid Leahy said the work of expanding education and access goes on.

One measure the state chapter is lobbying for would repeal the Parental Notice of Abortion Act which requires health care providers to notify the guardian of anyone under the age of 18 prior to performing an abortion. Another proposal aims to ensure more comprehensive sexual education throughout the state. "There is so much more work to do, we are not done. Holding the line and keeping the status quo is not enough," said Leahy.

Contact Rachel Otwell at rotwell@illinoistimes.com.

More here:
Abortion haven - Illinois Times

Recommendation and review posted by Bethany Smith

Actress Emma Roberts says she decided to freeze her eggs when she was diagnosed with endometriosis (Getty)

Emma Roberts has revealed she froze her eggs before falling pregnant with her partner, fellow actor Garrett Hedlund, earlier this year.

The 29-year-old actor told Cosmopolitan: A few years ago, I learned that Ive had undiagnosed endometriosis since I was a teenager. I always had debilitating cramps and periods, so bad that I would miss school and, later, have to cancel meetings. I mentioned this to my doctor, who didnt look into it and sent me on my way because maybe I was being dramatic?

Read more: These will be the biggest dating trends of 2021

Endometriosis affects around 10% of women and occurs when tissue similar to the lining of the womb grows in other places like the ovaries or fallopian tubes. It can cause debilitating cramps and can also contribute to infertility.

When Roberts was officially diagnosed, her doctor also recommended that she should freeze her eggs or look into other options.

Just the thought of going through that and finding out, perhaps, that I wouldnt be able to have kids I did freeze my eggs eventually, which was a difficult process, Roberts continued.

When I found out about my fertility, I was kind of stunned. It felt so permanent, and oddly, I felt like I had done something wrong.

The UK fertility regulator, the Human Fertilisation and Embryology Authority (HFEA), has allowed the use of frozen eggs in fertility treatment in the UK since 2000. But one cycle of egg freezing can cost up to 8,000. A large sum to pay when the birth rate from freezing your eggs is 18%.

Read more: Children as young as 11 are being prescribed nicotine patches by the NHS

However, the data shows that 1,463 of egg freezing cycles were completed in 2017, compared to just 234 in 2010. According to the HFEA, the number of women freezing their eggs in Britain jumped by 523% between 2013 and 2018. This number is only set to increase as clinics have also reported a 50% rise in egg freezing enquiries during lockdown.

Egg freezing has become more common in the last decade or so, as women tend to wait longer to start a family. The Mayo Clinic says egg freezing could be an option for women who dont want to get pregnant now, but might want to at a later date.

Egg freezing is often recommended to women who have a condition that can affect fertility, who need treatment for cancer or anyone who wants to preserve their eggs now for future use.

Watch: Five friends who struggled to fall pregnant have babies within weeks of each other

Firstly, if this is something youre considering then speak to your GP who can give you a full rundown of the options. Egg freezing is not normally available on the NHS unless you are having a medical treatment that could affect your fertility. So youll likely need to seek out a specialised clinic.

Once youre booked in, the process will typically take between two to three weeks. Youll then start IVF which includes two weeks of hormonal injections to help stimulate the ovaries to produce multiple eggs. The eggs are generally collected while the woman in under general anaesthetic and up to 15 eggs can be collected.

Read more: What is squamous cell bladder cancer and what are the symptoms?

Instead of being injected with sperm, as would happen with IVF, the eggs are added to the freezing solution and the eggs are then stored for up to a decade.

Once ready to use, the eggs are thawed and injected with sperm from a partner or a donor. If the egg is successfully fertilised, the embryo is then transferred to the womb in the hope it will lead to pregnancy.

Only a select few are eligible for egg freezing on the NHS, like cancer patients about to start chemotherapy. Most women looking to freeze their eggs will need to pay for it themselves, which can be costly as its unregulated and private clinics set the price.

If you are looking to freeze your eggs, you should budget around 8,000 for the entire process.

This includes 3,350 for the collecting and freezing process, 1,500 for the hormone injections, 350 a year to have your eggs stored and 2,500 for the thawing and embryo transfer process.

According to HFEA, age is the most important factor in success when it comes to freezing your eggs. For example, if a woman freezes her eggs before she is 35 shes more likely to conceive than if she tried to become pregnant naturally over the age of 40.

However, youll need to consider the age you will want to become pregnant, as the eggs can only be stored for 10 years. So if youre getting your eggs frozen at 25, youll need to use them by the time youre 35.

Originally posted here:
Emma Roberts reveals she froze her eggs after fertility struggle: Everything you need to know about the process - Yahoo India News

Recommendation and review posted by Bethany Smith

Al Roker revealed Friday that he has been diagnosed with prostate cancer, saying on NBCs Today show that it was discovered following a routine checkup in September.

"It's a good news-bad news kind of thing," the weatherman said. "Good news is we caught it early. [The] not great news is that it's a little aggressive, so I'm going to be taking some time off to take care of this."

Al Roker ( Nathan Congleton/NBC/NBCU Photo Bank via Getty Images)

Prostate cancer is one of the most common types of cancer in men. In fact, the American Cancer Society estimates that onein ninemen will be diagnosed with it during their lifetime.

Heres what to know about prostate cancer following the news of Rokers diagnosis.

NBC NEWS' AL ROKER ANNOUNCES PROSTATE CANCER DIAGNOSIS

What is prostate cancer and what causes it?

Prostate cancer is a cancer of the prostate, what theMayo Clinic describes as a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm.

Though its not entirely clear what causes prostate cancer, this type of cancer can form when cells in the prostate become abnormal, per the clinic. Not unlike other cancer types, mutations within the DNA of these abnormal cells cause them to grow and divide more quickly than normal, healthy cells.

AL ROKER OPENS UP ABOUT RAISING HIS SPECIAL-NEEDS TEENAGE SON: HE'S 'FULL OF LOVE TO SHARE'

The abnormal cells continue living when other cells would die. The accumulating abnormal cells form a tumor that can grow to invade nearby tissue. Some abnormal cells can also break off and spread (metastasize) to other parts of the body, according to the Mayo Clinic.

What are the signs of prostate cancer?

Prostate cancer usually grows slowly, so some men might not have any symptoms prior to their diagnosis. However, for some, prostate cancer can cause trouble urinating, blood in semen, discomfort in the pelvic area and erectile dysfunction, among other signs.

BELLY FAT MAY INCREASE DEATH FROM PROSTATE CANCER: STUDY

What are the risk factors?

The risk of prostate cancer typically increases with a mans age. Family history is also a factor, and chances can go up with obesity. Also, asRoker noted, Black men are more at risk for prostate cancer, although the reason for this is not clear. Its also more likely to be aggressive or advanced, according to the Mayo Clinic.

The American Cancer Society in its report entitled Cancer Facts & Figures for African Americans 2019-2021 saidprostate cancer is the most commonly diagnosed cancer in Black men.

How is prostate cancer treated?

In some cases, namely in those of low-risk prostate cancer, treatment right away may not be needed. In fact, some men may never need treatment. Instead, doctors sometimes recommend active surveillance, per the Mayo Clinic.

For more aggressive cases, surgery to remove the prostate may be required. Other treatment options include radiation therapy or hormone therapy. Freezing prostate tissue a process known as cryosurgery or cryoablation may also be recommended, as well as chemotherapy or biological therapy, according to the clinic.

Can prostate cancer be prevented?

In general, living a healthy lifestyle can help prevent prostate cancer in men. Eating a healthy diet full of fruits and vegetables as well as choosing healthy foods over supplements, exercising regularly and maintaining a healthy weight can all help to reduce the risk of a prostate cancer diagnosis, the Mayo Clinic says.

CLICK HERE TO GET THE FOX NEWS APP

Read more here:
Al Roker reveals prostate cancer diagnosis: What to know about one of the most common types of cancer in men - Fox News

Recommendation and review posted by Bethany Smith

Can hearts repair themselves via their own stem cells?

Sometimes what we scientists all know to be true turns out later on to be wrong and there are clear instancesof this in the stem cell field.

For example for decades the dogma was that the adult mammalianbrain did not have stem cells, but now most researchers believethat the adult brain does have stem cells, although for humans this is still being debated.

What we perceive as factual can change over time.

Yamanaka disproved the entrenched notion that differentiated cells were permanently locked into that differentiated state with his revolutionary findings on induced pluripotent stem cells. The new reality, which seemed revolutionary in some ways in 2006-2007, now is established fact.

So what about the idea of the human heart have resident populations of stem cells that can fix problems, perhaps as severe as damage from heart attacks? One of the first stem cell talks I ever saw way back around IPS cells were discovered was by a guy who assumed the factual answer to this question was Yes!

What about now in 2020? I have an ongoing Twitter poll on this question as of Nov. 5, 2020 so check it out below.

Today the cardiac regenerative field finds itself at an interesting crossroads.

A few say yes there are cardiac stem cells and that they can mediate repair. However, most heart researchers that Ive talked to in recent years feel just as strongly that there are no such cells. Some also have added that even if there are at least a handful of such cells or they arise due to damage, they cant do anything meaningful about serious heart damage.

I asked cardiac stem cell expert, Deepak Srivastava for his thoughts on this in a previous post and foundhis answercompelling. Because that was a fairly long time ago, I got an update to the same kind of question just now from two leading cardiac regenerative medicine and stem cell researchers.

Associate Professor of Medicine and Director of Cardiovascular Regenerative Medicine at Mt. Sinai, Hina Chaudhry had this to say:

One thing is certain: As both a clinical cardiologist who has cared for patients with heart attacks and a stem cell biologist, I can tell you that no scientific data supports an endogenous stem cell population in the adult heart and that no adult with a transmural myocardial infarction ever loses the resulting scar throughout their lifetime.

Professor Chuck Murry of the UW sent this:

Our current best evidence suggests that there are no stem cells in the adult heart that can give rise to new cardiomyocytes. This has been studied intensivelyfrom the bottom up, by tracing candidate stem cells and following their differentiated progeny, and from the top down by marking pre-existing cardiomyocytes and looking for their dilution as unmarked stem cells enter the pool. Both have shown the same thing: if this happens at all, its frequency is on the order of 10e-4 per year, which by any measure is next to nothing. There is slow turnover of cardiomyocytes in the adult mammalian heart, at ~1% per year, and this can be accounted for entirely by replication of pre-existing cardiomyocytes. One has to wonder, why has Nature done this? Why would such a vital organ have no stem cells for replenishment, along with such a low rate of endogenous replication?

I believe that Drs. Murry and Chaudhry are right. Chucks last question there is one for long discussions and is similar to discussions Ive had about the few stem cells/potential for endogenous repair in the adult human brain.

Still, you can find a diversity of papers now in 2020 in PubMed with Heart Regeneration or Cardiac Regeneration or Cardiac stem cells in their titles. However, many of the papers relate to stem cell infusions rather than invoking endogenous resident cells.

If not in humans, what about other mammals? There are glimpses of interesting possible stem cell activity in the mammalian heart, even if not in humans

A November 2014Cell Stem Cell paper from the lab of Juan Carlos Izpisua Belmonte, entitled InVivo Activation of a Conserved MicroRNA Program Induces Mammalian Heart Regeneration, argues for endogenous mammalian heart regeneration in part via dedifferentiation of cells into stem-like cells. This raises the interesting notion that while the mammalian heart does not normally have many (or any?) resident stem cells, damage can change some other cells into stem cell-like cells.

One of the biggest advocates of endogenous cardiac stem cells and repair, Piero Anversa formerly of Harvard and Brigham and Womens Hospital, has become one of the most controversial as well. His papers have come under fire and some have been retracted. Anversa was the subject of a Harvard investigation and was suing Harvard for how it has conducted the investigation and other matters related to his work.

In my view, his situation has raised even more skepticism about the idea of endogenous heart stem cells in people.

Even if the endogenous stem cell-like activity in the heart is absent or not enough to mediate clinically significant repair in humans, by deciphering the molecular basis of this kind of activity in other animals could the field still open the door to powerful new treatments for heart disease? For instance, if some adult mammalian hearts naturally replace 1 in 200 cells per year, perhaps cardiac researchers can find a way to boost that by an order of magnitude with a drug and have a meaningful impact for human patients.

Or if dedifferentiation of non-stem cells in the heart into stem cell-like cells can be induced by damage, could a drug therapy trigger that same effect even if damage occurred long ago or in the context of relatively minor damage?

Many researchers are focusing more on using injections of stem cells into the heart to repair damage. The types of stem cells being used for research attempts at heart repair are very diverse, including both placental cells and indirect use of IPS cells in Japan via a recently approved trial there.

Even the area of stem cell transplants into the heart generates its share of debate and well have to see in the long run how the clinical trial data turn out. I hope there can be positive impact in the future given the overwhelming number of people with heart damage.

Related

Read more:
Can Hearts Repair Themselves Via Stem Cells - The Niche

Recommendation and review posted by Bethany Smith

Heart Diseases are serious and global public health concern. In spite of remarkable therapeutic developments, the prediction of patients with Heart Failure (HF) is weak, and present therapeutic attitudes do not report the fundamental problem of the cardiac tissue loss. Innovative therapies are required to reduce mortality and limit or abolish the necessity for cardiac transplantation. Stem cell-based therapies applied to the treatment of heart disease is according to the understanding that natural self-renewing procedures are inherent to the myocardium, nonetheless may not be adequate to recover the infarcted heart muscle. Following the first account of cell therapy in heart diseases, examination has kept up to rapidity; besides, several animals and human clinical trials have been conducted to preserve the capacity of numerous stem cell population in advance cardiac function and decrease infarct size. The purpose of this study was to censoriously evaluate the works performed regarding the usage of four major subgroups of stem cells, including induced Pluripotent Stem Cells (iPSC), Embryonic Stem Cells (ESCs), Cardiac Stem Cells (CDC), and Skeletal Myoblasts, in heart diseases, at the preclinical and clinical studies. Moreover, it is aimed to argue the existing disagreements, unsolved problems, and prospect directions.

Keywords: Heart disease; Myocardial regeneration; Stem cells; Tissue repair.

Read the original post:
Stem cells as therapy for heart disease: iPSCs, ESCs, CSCs ...

Recommendation and review posted by Bethany Smith

.biz has announced a business intelligence study on Global Autologous Stem Cell Based Therapies Market 2020 by Company, Type and Application, Forecast to 2025 that reveals diverse information allowing keen market participants to understand the measures of the market. The report sheds light on market developments, noteworthy trends as well as competitive vendor activities and performance analysis. The report is aimed at offering readers real-time data vital to drive future-ready investment decisions. The research focuses on the dominant trends, persistent challenges, and threats, as well as budding opportunities influencing growth scenarios in the global Autologous Stem Cell Based Therapies market. The market report is a comprehensive research that demonstrates overall consumption structure, development trends, well-known providers, and market segments.

Executive Summary:

The report assesses the historical and future timelines, accurate growth predictions, and forecast estimations, and fast-changing market forces. The report draws references for an extensive analysis of the global Autologous Stem Cell Based Therapies market, entailing important details about key market players, with a broad overview of expansion probability and expansion strategies. The report has been designed and presented in the form of tables and figures and other statistical to generate higher reader perception. Later in the report, details on manufacturer information, leading market participants as well as other key players have also been added.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/67562

Understanding Scope:

Leading companies covered in the report include: Regeneus, US STEM CELL, INC., Mesoblast, Med cell Europe, Pluristem Therapeutics Inc, Tigenix, Brainstorm Cell Therapeutics

By the product type, the market is primarily split into: Embryonic Stem Cell, Resident Cardiac Stem Cells, Umbilical Cord Blood Stem Cells

By the end-users/application, this report covers the following segments: Neurodegenerative Disorders, Autoimmune Diseases, Cardiovascular Diseases

The report contains detailed market size and forecast for the following countries and regions: North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/67562/global-autologous-stem-cell-based-therapies-market-2020-by-company-type-and-application-forecast-to-2025

Moreover, upstream raw materials, downstream demand analysis, and end-user industry listings have been studied with vendors in this global Autologous Stem Cell Based Therapies market. Product flows and distribution channels were also presented in this research report. The report includes broad market segmentation based on the different product types, a wide application spectrum, the key regions, and the existing competition among players. In addition, the report reviews pricing analysis, profit margins, cost and demand volatility, import/export dynamics, gross revenue, and various other aspects of the market.

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Read more:
Global Autologous Stem Cell Based Therapies Market 2020 Segmentation, Statistics, Top Manufacturers, Regional Analysis and Forecast to 2025 - The...

Recommendation and review posted by Bethany Smith

Stem cells are biological cells which have the ability to distinguish into specialized cells, which are capable of cell division through mitosis. Amniotic fluid stem cells are a collective mixture of stem cells obtained from amniotic tissues and fluid. Amniotic fluid is clear, slightly yellowish liquid which surrounds the fetus during pregnancy and is discarded as medical waste during caesarean section deliveries. Amniotic fluid is a source of valuable biological material which includes stem cells which can be potentially used in cell therapy and regenerative therapies. Amniotic fluid stem cells can be developed into a different type of tissues such as cartilage, skin, cardiac nerves, bone, and muscles. Amniotic fluid stem cells are able to find the damaged joint caused by rheumatoid arthritis and differentiate tissues which are damaged.

For more insights into the Market, request a sample of this report @https://www.persistencemarketresearch.com/samples/23101

Medical conditions where no drug is able to lessen the symptoms and begin the healing process are the major target for amniotic fluid stem cell therapy. Amniotic fluid stem cells therapy is a solution to those patients who do not want to undergo surgery. Amniotic fluid has a high concentration of stem cells, cytokines, proteins and other important components. Amniotic fluid stem cell therapy is safe and effective treatment which contain growth factor helps to stimulate tissue growth, naturally reduce inflammation. Amniotic fluid also contains hyaluronic acid which acts as a lubricant and promotes cartilage growth.

With increasing technological advancement in the healthcare, amniotic fluid stem cell therapy has more advantage over the other therapy. Amniotic fluid stem cell therapy eliminates the chances of surgery and organs are regenerated, without causing any damage. These are some of the factors driving the growth of amniotic fluid stem cell therapy market over the forecast period. Increasing prevalence of chronic diseases which can be treated with the amniotic fluid stem cell therapy propel the market growth for amniotic fluid stem cell therapy, globally. Increasing funding by the government in research and development of stem cell therapy may drive the amniotic fluid stem cell therapy market growth. But, high procedure cost, difficulties in collecting the amniotic fluid and lack of reimbursement policies hinder the growth of amniotic fluid stem cell therapy market.

For Information On The Research Methodology request here @https://www.persistencemarketresearch.com/methodology/23101

The global amniotic fluid stem cell therapy market is segmented on basis of treatment, application, end user and geography:

To receive extensive list of important regions, Request TOC here @https://www.persistencemarketresearch.com/toc/23101

Rapid technological advancement in healthcare, and favorable results of the amniotic fluid stem cells therapy will increase the market for amniotic fluid stem cell therapy over the forecast period. Increasing public-private investment for stem cells in managing disease and improving healthcare infrastructure are expected to propel the growth of the amniotic fluid stem cell therapy market.

However, on the basis of geography, global Amniotic Fluid Stem Cell Therapy Market is segmented into six key regionsviz. North America, Latin America, Europe, Asia Pacific Excluding China, China and Middle East & Africa. North America captured the largest shares in global Amniotic Fluid Stem Cell Therapy Market and is projected to continue over the forecast period owing to technological advancement in the healthcare and growing awareness among the population towards the new research and development in the stem cell therapy. Europe is expected to account for the second largest revenue share in the amniotic fluid stem cell therapy market. The Asia Pacific is anticipated to have rapid growth in near future owing to increasing healthcare set up and improving healthcare expenditure. Latin America and the Middle East and Africa account for slow growth in the market of amniotic fluid stem cell therapy due to lack of medical facilities and technical knowledge.

Some of the key players operating in global amniotic fluid stem cell therapy market are Stem Shot, Provia Laboratories LLC, Thermo Fisher Scientific Inc. Mesoblast Ltd., Roslin Cells, Regeneus Ltd. etc. among others.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Naved BegPersistence Market ResearchAddress 305 Broadway, 7th Floor New York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Visit link:
The Amniotic Fluid Stem Cell Therapy market to be in conjunction to growth from 2018 to 2026 - PRnews Leader

Recommendation and review posted by Bethany Smith

SAN CARLOS, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BioCardia, Inc.[NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and business highlights for the third quarter of 2020 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 with the Securities and Exchange Commission on November 10, 2020.

The Company is advancing its autologous and allogenic bone marrow-derived cell therapies for three cardiovascular indications and one respiratory indication.

Third Quarter 2020 Business Highlights:

Autologous Cell Therapies

Allogenic Cell Therapies

Corporate Developments

We are reaching critical milestones in our cardiovascular and respiratory cell therapy development programs at a time when patients are increasingly presenting with heart damage due to COVID-19, said BioCardia CEO Peter Altman, PhD. We believe that the clinical data supports patient benefit through paracrine mechanisms, which differs from those attempting to transform cells into new heart cells, and believe that the approach has tremendous promise to help patients suffering from severe heart and respiratory diseases.

Third Quarter 2020 Financial Results:

Anticipated Upcoming Milestones in Q4 2020:

About BioCardiaBioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Companys biotherapeutic platforms in clinical development. The Company's products include the Helix Biotherapeutic Delivery System and its steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix system and clinical support for their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visit http://www.BioCardia.com.

Forward Looking StatementsThis press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, references to the enrollment of our clinical trials, the availability of data from our clinical trials, filings with the FDA, FDA product clearances, the efficacy and safety of our products and therapies, anticipated milestones, and other statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, regulatory approvals, unexpected expenditures, the ability to raise the additional funding needed to continue to pursue BioCardias business and product development plans and overall market conditions.We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control.Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent development of our therapeutic candidates.These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.

We may use terms such as believes, estimates, anticipates, expects, plans, intends, may, could, might, will, should, approximately or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate.Additional factors that could materially affect actual results can be found in our documents filed with the SEC, including our recent filings on Form 8-K, Form 10-K and Form 10-Q, particularly any statements under the caption entitled Risk Factors Therein. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Media Contact:Michelle McAdam, Chronic Communications, Inc.michelle@chronic-comm.com(310) 902-1274

Investor Contact:David McClung, Chief Financial OfficerInvestors@BioCardia.com(650) 226-0120

BIOCARDIA, INC.Condensed Statements of Operations(Unaudited In thousands, except share and per share amounts)

Follow this link:
BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights - GlobeNewswire

Recommendation and review posted by Bethany Smith

One of the biggest challenges that scientists and healthcare professionals are facing during the COVID-19 pandemic is the high rate of clinical variability. Whilst some patients present as asymptomatic, others are developing more severe symptoms such as pneumonia, and some cases are ultimately proving fatal. Why?The answer remains elusive; however, extensive research is exploring the possible contribution our genetics may be having. Genetic variation differences in the DNA sequences that make up our genome can impact our response to infectious diseases.

GoodCell uniquely measures and monitors inherited and acquired genetic variations in stem cells and other nucleated cells in our blood over time. Technology Networks recently spoke with Dr Salvatore Viscomi, chief medical officer at GoodCell, and attending physical at Baystate Health, to explore factors that might influence COVID-19 risk, and to discuss how the company is working to identify at-risk individuals through genetic variation analysis.

Molly Campbell (MC): For our readers that may be unfamiliar, can you discuss why medicine is moving towards a personalized approach, and why this is important considering genetic variation?Salvatore Viscomi (SV): Healthcare has traditionally taken the approach of one size fits all in defining individual risk for a disease and prescribing therapy for it. Understanding the differences between individuals on a molecular level optimizes assessment of an individuals susceptibility to a certain disease and predicting response to pharmacological therapy. Genomics plays the most important role in the emergence of personalized therapy. Identifying the inherited and acquired genetic variation will direct personalized screening and prevention plans and inform bespoke medical therapies.

MC: We know that there is high clinical variability across COVID-19 patients. How might genetic variation be contributing here, and what published evidence exists to support this?SV: Understanding immune response is critical to identifying individuals at high risk of severe morbidity and mortality. Emerging research suggests that accumulated genetic variation in our blood cells may be associated with a dysfunctional inflammatory response to COVID-19 leading to its pulmonary, cardiac and coagulopathic complications.

In a recent study published by JAMA Cardiology, researchers demonstrated an association between the presence of accumulated genetic change in our blood cells and a pro-inflammatory immune response that resembles the exaggerated cytokine release syndrome (CRS) manifested in COVID-19-positive patients. Direct evidence has emerged more recently; a study published in Cancers examined patients hospitalized with COVID-19 and found a significantly higher prevalence of accumulated genetic variation in all age groups compared to age-matched control groups.

MC: What impact might genetic variation in COVID-19 patients have on efforts to develop therapeutics or preventives, such as vaccines?SV: Identifying highly susceptible individuals through blood testing could have many applications. As an initial wave of vaccines move through Phase III trials and potentially come to market, we would have the data to determine prioritization of vaccinations when one is available. Business and government sectors need insight into risk factors that can inform inoculation strategies for societys most vulnerable, inform decisions around who should and should not be on the front lines, and give people more control when making personal decisions about how to mitigate individual risk. The broader field of genetics offers a window into the potential to correlate inherited and acquired gene mutations with immune response for the betterment of society, providing a more robust and accurate set of risk factors unique to every individual.

Furthermore, in high-risk individuals, targeting inflammation may be a clinical strategy to mitigate its clinical consequencesin COVID-19. For example, we may identify patients who are most responsive to pro-inflammatory inhibitors. Implementing measures intended to reduce subjects exposure to the infection or likelihood of contracting such infection through self-isolation, quarantine or social distancing may be advised.

MC: Can you explain the aims of GoodCell, and what the company does in terms of "banking blood for life"?SV: GoodCells mission is to extend and improve the quality of life through technology powered by our own cells. Blood is the author of our bodies, and can both cure as well as cause disease. Through our proprietary data aggregation and analytics technology platform, which aims to decode our blood cells and harness their insights to advance population and personal health, we empower individuals to identify, track and mitigate health risks. By getting ahead of their health risks, we enable the potential for a better life. In addition, through our personal biobanking service, long-term storage of your healthiest cells provides the opportunity for potential use in future therapeutics if you need them you are your best donor.

MC: Does GoodCell measure other "omics" parameters outside of genomics (DNA measurements and analysis), such as proteomics or metabolomics?SV: GoodCells platform leverages the power of blood to assess risk as such, we of course look at acquired and inherited genetic changes, but there are many more opportunities afforded by blood to understand and assess risk including routine blood chemistry tests, tests for biomarkers of disease, including emerging capabilities in liquid biopsy for earlier detection of solid tumor cancers. Ultimately, we are always looking to incorporate novel health and data insights into our product platform to better inform both an individuals health, as well as population-based health. Transcriptomics, epigenomics and metabolomics are but a few of the opportunities we are evaluating.

MC: What work is GoodCell currently conducting in the COVID-19 space?SV: GoodCell is currently engaged in a research collaboration with the New York Blood Center to evaluate how specific acquired and inherited genetic variation contribute to COVID-19 severity and recovery. We are analyzing genetic variation in asymptomatic/mildly symptomatic patients compared to hospitalized/ICU patients. GoodCell will evaluate the genetic variation in the collected samples using our proprietary assay platform to identify and validate their association with COVID-19 morbidity and mortality.

Salvatore Viscomi was speaking to Molly Campbell, Science Writer, Technology Networks.

Visit link:
Exploring Genetic Variation and COVID-19 Clinical Variability - Technology Networks

Recommendation and review posted by Bethany Smith

WINNIPEG -- A baby boy in Winnipeg is in need of a bone marrow transplant to survive, but he has yet to find a donor.

Three-month-old Boston has a rare disease called hemophagocytic lymphohistiocytosis HLH, a rare auto-inflammatory condition with his immune system.

His mother Simone Jannetta, who is a nurse at Grace Hospital, said they need someone who is of mixed race to donate stem cells.

Thats the only way to cure this, she said.

In the meantime, hes just receiving chemotherapy and steroids to help keep him well until then."

Jannetta said the reason they are having difficulty finding a match is because they need someone half Filipino and half Caucasian, and there are not many mixed-race donors currently in the Canadian and worldwide stem cell registries.

A TOUGH ROAD FOR FAMILY DEALING WITH HEALTH ISSUES

This is not the first time the family has dealt with a child facing health issues over the last few years.

When Jannettas daughter and Bostons older sister Beatrix was seven-months-old she presented to the emergency department with a fever and low blood counts. After a bone marrow biopsy, they learned she had a rare condition called autoimmune neutropenia.

So her immune system is not well either, shes very susceptible to infection too, Jannetta said.

Weve had a lot of back and forth with the hospital through herits been a tough road for us.

Anyone in Canada who wants to register to see if they are a match for Boston can go to the Canadian Blood Services website and look up the stem cell registry.

Boston also has his own link where you can register. The Canadian Blood Services will then mail you a kit with a swab, which you can send back once completed.

Its that simple, Jannetta said.

Youre put on the registry and Boston can then match with somebody.

For anyone who is thinking about registering to become a stem cell donor, Jannetta wants them to know they could save somebodys life.

Its not hard, theres no obligation follow through even if you do register, she said.

Theres just such a small representation of ethnically-diverse people on the registry and I just feel like everybody deserves a chance.

- With files from CTVs Nicole Dube.

See the rest here:
Three-month-old Winnipeg boy in need of bone marrow transplant to survive - CTV News Winnipeg

Recommendation and review posted by Bethany Smith

Voters in California have approved Proposition 14, which will pump billions of dollars into the state's stem cell research program. The Associated Press called the vote on Thursday, with 51 percent of ballots for and 49 percent against.

The result will allow the state to borrow $5.5 billion from investors for its stem cell agency, the California Institute for Regenerative Medicine (CIRM). The moneywhich taxpayers will repay with interest over the next 30 yearswill enable the institute to stay open, expand its research programs, and build new facilities.

Some $1.5 billion of the money will be spent researching conditions affecting the brain and central nervous system, such as Alzheimer's, Parkinson's, epilepsy, and stroke.

Unlike specialized cellssuch as blood cells or bone cellsstem cells do not have a specific job. Think of them as the raw materials of our bodies. When they divide, they can either renew and make new stem cells, or turn into specialized cells.

Despite making headlines for years, stem cell research is still in its early stages, with some treatments that have appeared to have worked in animals now going into clinical trials. These include treatments for macular degeneration, a common cause of blindness, as well as stroke, Lou Gehrig's disease, and spinal cord injuries.

It is hoped growing stem cells into specialized cells could also one day be used to replace damaged tissue and organs, for instance by helping the pancreas produce insulin in people with diabetes.

Currently, stem bone marrow transplantation is the most common form of stem cell therapy, used to treat blood cancer patients. Stem cell therapy has also been used for grafts of corneal stem cells, as well as skin grafts for burns victims.

As well as creating treatments, stem cell research can also help scientists understand diseases. Observing the cells in a lab as they turn into specialized cells, for instance, can provide clues on how we develop certain conditions.

There are a number of stem cells: embryonic stem cells, adult stem cells, adult stem cells tweaked to behave like embryonic stem cells, and stem cells found in the amniotic fluid and the umbilical cord of babies.

The controversy around stem cell research largely lies in the use of embryonic stem cells. These are taken from human embryos in their early stages of development. Opponents have likened this to abortion, although others disagree with this stance.

Embryonic stem cells used in research come from donations from IVF clinics, where an egg is fertilized with a sperm but not implanted into a patient because it is not needed. Embryonic stem cells are preferred over adult stem cells, as it may not be possible to specialize the latter and they are more likely to have abnormalities. But research suggests that it may be possible to turn adult stem cells into a wider range of specialized cells than previously thought, which may make them more useful.

In 2001, the Bush administration banned federal funding for stem cell research. This lead real estate developer Robert N. Klein II to initiate and help fund Proposition 71 in California. The aim was to enshrine the right to carry out stem cell research in the state's constitution, and establish CIRM. Klein was motivated by his son's experience with Type 1 diabetes, and his mother's Alzheimer's diagnosis. In 2004, Californians voted in favor of the proposition.

The institute has performed 64 clinical trials, and published over 3,000 scientific articles on the subject. But 16 years after Proposition 71 passed, CIRM started to run out of funds, and stopped accepting applications for new projects last year. This prompted the Californians for Stem Cell Research, Treatments and Cures political action committee (PAC) to lead the campaign for Proposition 14. Klein was among its supporters, as well as California governor Gavin Newsom, LA mayor Eric Garcetti, and the Michael J. Fox Foundation established by the Back to the Future actor and Parkison's disease patient who is its namesake.

On November 1, the foundation urged people via Twitter to vote in favor of Prop 14 to fund research on neurological disease. "Without this proposition vital research may come to a halt, delaying new treatments for people with," it said.

Read the rest here:
As California Passes Prop 14, What Is Stem Cell Research and Why Is It Controversial? - Newsweek

Recommendation and review posted by Bethany Smith

Paula Grisanti, Opinion contributor Published 6:20 a.m. ET Nov. 9, 2020

This year, Nov.17 has been designated World Cord Blood Day, an annual event to raise awareness for the life-saving benefits of cord blood transplants while educating parents, health professionals and the general public about the need to preserve these precious cells.

Cord blood transplants are being used to treat more than 80 different diseases and conditions including blood cancers like leukemia and lymphoma, neuroblastoma (the most common cancer in infants), bone-marrow failure disorders, inherited blood disorders and rare immune system disorders. They are also showing new promise for conditions that have never had treatment options, like autism and brain injury.

The first cord blood stem cell transplant, an international effort between physicians in the U.S. and Europe, was performed in France in 1988. Stem cells collected from a newborns umbilical cord blood were used to save the life of her brother, a 5-year-old with Fanconi Anemia. Since then, there have been more than 40,000 cord blood transplants performed worldwide.

Now standard of care for cancers of the blood and a host of other life-threatening diseases, blood forming stem cells for transplantation can be collected from bone marrow, circulating bloodor a newborn babys umbilical cord blood. Some experts believe cord blood contains nearly 10 times the number of stem cells found in bone marrow.

Because umbilical cord stem cells are less mature than adult bone marrow stem cells, they are also less likely to be rejected and can be used when there isnt a perfect match.

Between these threeoptions, the easiest collection by far is from umbilical cord and placental tissue after a baby is born and the umbilical cord has been cut, at no risk to mother or child, in a process that typically takes 5 to 10 minutes. The cells are then frozen in liquid nitrogen and can be stored indefinitely in private or public cord blood banks.

To store your babys cord blood for use by your child and your family only, you make arrangements with a private cord blood bank ahead of delivery to collect and store the cells; the cost to you includes a collection fee of $1,500 to $2,000 and an annual storage fee of $100 to $125.

If you cant afford or dont wish to save your babys cord blood stem cells, you can donate them to a public cord blood bank at no cost to you or your family.

Its the equivalent of registering these potentially life-saving cells with the national bone marrow registry; they will be available to the families of other children who need to find a bone marrow match after a devastating diagnosis. Without information and education, however, 95% of all cord blood is discarded as medical waste.

Right now, there is no public cord banking option in Kentucky, although public cord blood banking is highly recommended by both the American Academy of Pediatrics (AAP) and the American Medical Association (AMA). There are fewer than 25 public or hybrid cord blood banks in the U.S., many limited to a specific geographic area. None of them include Kentucky.

The chances of finding a bone marrow match in your family are only about 25%, making the bone marrow and umbilical cord blood registries a lifeline in desperate situations. Odds are worse for African Americans and other ethnic minorities who are underrepresented on the registry and ethnicity matters in a bone marrow transplant.

Donating cord blood cells to a public bank adds to the library of cells that may save someones life and increases the chance of a match for all of us. Who benefits most? Children, patients with rare human leukocyte antigen (HLA) types and ethnic minorities.

We need to do two things: Make public cord blood banking an option in the commonwealth of Kentucky, and then encourage conversations between health care providers and expectant parents about preserving these life-saving cells.

There are 28 states with legislation that ask or mandates physicians to talk to expectant parents about cord blood banking. Kentucky is not one of them, but most of our surrounding states have such legislation in place.

Through a long-standing relationship between the National Stem Cell Foundationand world-renowned cord blood expert Dr. Joanne Kurtzberg, we have a path forward for training hospitals and collecting cells for storage at the Carolinas Cord Blood Bank (CCBB), one of the largest public cord blood banks in the world. Dr. Kurtzberg directs both the Pediatric Blood and Marrow Transplant (PBMT) program at Duke University and the CCBB.

She performed the worlds first unrelated cord blood transplant in 1993, paving the way for this now routine source of donor cells for children who need a bone marrow transplant and dont have a matched donor. She established the CCBB in 1998.

Paula Grisanti is CEO of the National Stem Cell Foundation.(Photo: provided)

While weve initiated discussions between Louisville hospital systems and the CCBB, we need to begin the process of education for parents, nursing and medical school students, residents, midwives, practicing OB-GYNs and the general public.

What a waste to discard these life-saving cells the future of current and developing therapies for disabling and life-threatening diseases depends on our ability to make sure that doesnt happen.

Dr. Paula Grisanti is CEO and a founding member of the National Stem Cell Foundation, headquartered in Louisville, Kentucky. She holds a D.M.D. and MBA from the University of Louisville and has been actively involved in new venture start-ups for most of her career.

Read or Share this story: https://www.courier-journal.com/story/opinion/2020/11/09/expectant-parents-need-to-know-benefits-of-cord-blood-banking/6064540002/

Originally posted here:
It's time for Kentucky to talk to expectant parents about benefits of cord blood banking - Courier Journal

Recommendation and review posted by Bethany Smith

Troy McKinley donated stem cells to help a stranger with blood cancer.

Think about your birthday wish this year? Did it involve saving someone's life?

A Reynoldsburg man's wish did.

Thirty-five-year-olf Troy McKinely wanted to make sure his birthday wish made a difference in someone else's life.

I wanted to do something big if possible. I've never donated blood before I don't even like needles, he said.

Two years ago, he decided he wanted to make his birthday more about gifts, and instead give the gift of life.

I thought it would be great to save a life so what can I do to help, he said

He found DKMS, the world's largest bone marrow and blood stem cell donor center.

The company sent him a swab kit and he waited to see if he would be a match. Two and a half years later, he was notified that his stem cells matched a patient who was diagnosed with blood cancer.

It was kind of like 'wow this is big. I don't know this person. I don't know anything about him or her.' It's kind of amazing feeling that it could be better for somebody else, he said.

McKinley said it only took a few hours to give the needed stem cells that doctors would later implant to the unknown patient.

I'm hoping that this gentleman I helped is feeling better for it and helped him in some way. Maybe it didn't give him everything back but he has some more time and we all want more time in the world so hopefully, it helped him, he said.

Time, we can all use more of it, but how many of us take the time to think about how we can give others more days on this earth.

It was a birthday wish McKinley says he'd do again knowing his kindness gave a stranger something more valuable than anything.

I think it's amazing to save someone's life. It's an incredible experience, he said.

About DKMS

Read the original here:
Reynoldsburg man makes unusual birthday wish: 'I wanted to save someone's life' - 10TV

Recommendation and review posted by Bethany Smith

During a 2018 home game against Washington State University, David Shaw, Stanford's football coach, ambled slowly along the sideline, his joints aching.

Wanting to focus on the players and the game, he kept the reason for his lethargy to himself. But two years later, this past Saturday, the sports world learned the full story.

A College GameDay feature on ESPN revealed that the morning before the game, Shaw had been given stem-cell-inducing medication at Stanford Hospital. It was a first step in donating the cells to his brother, Eric Shaw, who was fighting a rare form of lymphoma.

In the opening of the six-minute video, Shaw says he thought, "'God, I hope this works, 'cause if it doesn't, I'm going to lose my brother.'"

Eric Shaw began noticing strange dark patches on his skin in 2011, the year his older brother became Stanford's head football coach. They were everywhere, from head to foot. Later, small tumors popped up all over his body.

"I would have itching attacks where I would end up actually tearing my skin," he says in the video. "I would still scratch at night and end up with bloody arms and legs."

Eric Shaw transferred his medical care to the Stanford Cancer Center in 2013. There, physicians told the financial services marketing professional that he needed to start radiation treatment immediately. It worked, but only briefly: Six months later, the cancer returned.

He was diagnosed with mycosis fungoides, a T cell lymphoma that affects fewer than four in a million people in the United States.

Shaw's physicians began discussing bone marrow transplant. David Shaw was tested as a donor, but he scored only 5 on a 10-point match scale. A worldwide search found closer matches, and Eric Shaw underwent radiation and chemotherapy to prepare for the transplant.

One attempt failed, then another.

"You think you've kind of pulled at the last thread, and there are no more threads, and all I could tell him was that I loved him and that I was there for him," David Shaw says in the video.

But the Stanford physicians had one last weapon: a haploidentical transplant. The recently developed technique uses stem cells, typically from a family member, that are less than a perfect match.

David Shaw underwent a five-day-long process at Stanford Hospital to donate the cells. He received medication that caused him to produce an abundance of stem cells, then gave blood from which the cells were extracted. Those cells were then transplanted into his brother.

This time, it worked.

After 52 days at Stanford Hospital, Eric Shaw finally went home on Nov. 25, 2018. The video shows him being wheeled out as medical staff members cheer him on.

Youn Kim, MD, who treated Eric and heads Stanford's multidisciplinary Cutaneous Lymphoma Clinic/Program, told ESPN: "If he didn't go for this risk, he wouldn't be here...He wouldn't be living."

As the article notes, Stanford physicians Wen-Kai Weng, MD, PhD, and Michael Khodadoust, MD, PhD, also were on the team treating Eric Shaw.

Today, nearly two years later, he remains cancer-free.

"Seven years of battling this disease, and it was over," he says in the video, tears running down his face. "A miracle."

David Shaw shares his brother's joy. As he told ESPN: "Every time I see him, I just smile, you know? Because he gets to be here."

Images of Eric Shaw, left, taken earlier this month, and his brother David Shaw, courtesy of the Shaw family, and Stanford Athletics

Continued here:
Stanford coach's quest to save his brother: 'God, I hope this works' - Scope

Recommendation and review posted by Bethany Smith

Rheumatoid arthritis refers to an inflammatory disease of the supportive tissues of the body and the condition generally affects fingers and toes of human beings. This inflammation is caused by an abnormal response of the body to the normal functioning tissues. This leads to acute pain and malformed joints. Novel cells that are produced by regenerative centers of the body are called stem cells. These cells can be changed into any other type of cell in the body with just the right kind of stimulant. The growth of the global rheumatoid arthritis stem cell therapy market is likely to observe growth in its ability to demonstrate profound healing activity. It also helps in checking the arthritic condition. In addition to that, this therapy is capable of regenerating and reversing joint tissue in many cases, which is likely to pave way for rapid growth of the global rheumatoid arthritis stem cell therapy market in the years to come.

Get SampleCopy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6864

Ability to Diminish Pain and Inflammation to Bolster Demand in the Market

In present times, human umbilical cord tissue (allogeneic mesenchymal stem cells), fat-derived or adipose stem cells, and bone marrow transplant are utilized for the purpose of the rheumatoid arthritis stem cell therapy. As the condition becomes worse, the body starts autoimmune response and keeps on attacking the cells of the body. The global rheumatoid arthritis stem cell therapy market is estimated to gather momentum from its growing importance and popularity in specialty clinics, ambulatory surgical centers, and hospitals. This therapy comes with the excellent healing capabilities that can treat the entire system causing inflammation and joint pain.

Extensive growth opportunities of the global rheumatoid arthritis stem cell therapy market are likely to be influenced by the multiple benefits offered by this therapy. However, this therapy comes with its own share of disadvantages as well and is not an infallible method for healing arthritis. All though, this therapy is capable of assisting in the stabilization of the body immune system and diminish inflammation.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6864

Like Loading...

As Head of Marketing at TMR Research, Rohit brings to the table over a decade of experience in market research and Internet marketing. His dedication, perseverance, and passion for perfection have enabled him to achieve immense success in his field. Rohit is an expert at formulating new business plans and strategies to help boost web traffic. His interests lie in writing news articles on technology,healthcare and business.View all posts by Rohit Bhisey

Read more here:
Rheumatoid Arthritis Stem Cell Therapy Market to Ride on Increased Prevalence of Rheumatoid Arthritis - TMR Research Blog

Recommendation and review posted by Bethany Smith

Stem cell banking or preservation is a combined process of extraction, processing and storage of stem cells, so that they may be used for treatment of various medical conditions in the future, when required. Stem cells have the amazing power to get transformed into any tissue or organ in the body. In recent days, stem cells are used to treat variety of life-threatening diseases such as blood and bone marrow diseases, blood cancers, and immune disorders among others.

The study provides details such as the market share, Market Insights, Strategic Insights, Segmentation and key players in the Stem Cell Banking Market.

Download PDF Report Sample with statistical info @ https://www.theinsightpartners.com/sample/TIPBT00002082/

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The global stem cell banking market is segmented on the basis of source, service type, and application. The source segment includes, placental stem cells (PSCS), dental pulp-derived stem cells (DPSCS), bone marrow-derived stem cells (BMSCS), adipose tissue-derived stem cells (ADSCS), human embryo-derived stem cells (HESCS), and other stem cell sources. Based on service type the market is segmented into, sample processing, sample analysis, sample preservation and storage, sample collection and transportation. Based on application, the market is segmented as, clinical applications, research applications, and personalized banking applications.

Note The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries. This report on Stem Cell Banking Market provides the analysis on impact on Covid-19 on various business segments and country markets. The reports also showcase market trends and forecast to 2027, factoring the impact of Covid -19 Situation.

The researchers have analysed the competitive advantages of those involved in the industries or in the In Stem Cell Banking industry. While historical years were taken as 2020 2027, the base year for the study was 2020. Similarly, the report has given its projection for the year 2020 apart from the outlook for years 2020 2027.

Some of the Major Market Players Are:

Cordlife, ViaCord (A Subsidiary of PerkinElmer), Cryo-Save AG, StemCyte India Therapeutics Pvt. Ltd., Cryo-Cell International, Inc., SMART CELLS PLUS, Vita 34, LifeCell, Global Cord Blood Corporation, CBR Systems

The objective of the researchers is to find out the sales, value, and status of the In Stem Cell Banking industry at the international levels. While the status covers the years of 2020 2027, the forecast is for the period 2020 2027 that will enable market players to not only plan but also execute strategies based on the market needs.

The study wanted to focus on key manufacturers, competitive landscape, and SWOT analysis for the In Stem Cell Banking Market. Apart from looking into the geographical regions, the report concentrated on key trends and segments that are either driving or preventing the growth of the industry. Researchers have also focused on individual growth trends besides their contribution to the overall market.

An outline of the regional analysis:

In Stem Cell Banking market recent innovations and major events.

Additional highlights of the In Stem Cell Banking market report:

Purchase This Report at: https://www.theinsightpartners.com/buy/TIPBT00002082/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Life Science, Technology, Healthcare, Manufacturing, Automotive and Defense, Food Beverages, Chemical etc.

Contact Us:

Call: +1-646-491-9876

Email: [emailprotected]

Read the original post:
Stem Cell Banking Market To See Massive Growth By 2027| Cryo-Save AG, StemCyte India Therapeutics, SMART CELLS PLUS, Vita 34, LifeCell - PRnews Leader

Recommendation and review posted by Bethany Smith

Overview for Stem Cell Banking Market Helps in providing scope and definitions, Key Findings, Growth Drivers, and Various Dynamics.

The Stem Cell Banking market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Stem Cell Banking market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Stem Cell Banking market. The report focuses on well-known providers in the global Stem Cell Banking industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Stem Cell Banking Industry will develop is also analyzed in detail in Chapter 1.7 of the report., In Chapter 2.4, we analyzed industry trends in the context of COVID-19., In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets., In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries., In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Download PDF Sample of Stem Cell Banking Market report @ https://www.arcognizance.com/enquiry-sample/1315141

Key players in the global Stem Cell Banking market covered in Chapter 4:, Boyalife, StemCyte, Crioestaminal, Esperite, Americord, Cryo-cell, PBKM FamiCord, Beikebiotech, PacifiCord, RMS Regrow, Stemade Biotech, Krio, CCBC, Cordlife Group, Cellsafe Biotech Group, Vcanbio, Familycord, ViaCord, Cells4life, LifeCell, CBR, Cryo Stemcell

In Chapter 11 and 13.3, on the basis of types, the Stem Cell Banking market from 2015 to 2026 is primarily split into:, Placental Stem Cells (PSCs), Human Embryo-derived Stem Cells (HESCs), Bone Marrow-derived Stem Cells (BMSCs), Adipose Tissue-derived Stem Cells (ADSCs), Dental Pulp-derived Stem Cells (DPSCs), Other Stem Cell Sources

In Chapter 12 and 13.4, on the basis of applications, the Stem Cell Banking market from 2015 to 2026 covers:, Personalized Banking Applications, Clinical Applications, Hematopoietic Disorders, Autoimmune Disorders, Other Diseases, Research Applications, Disease Treatment Studies, Life Science Research, Drug Discovery

[emailprotected] https://www.arcognizance.com/discount/1315141

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:, North America (Covered in Chapter 6 and 13), United States, Canada, Mexico, Europe (Covered in Chapter 7 and 13), Germany, UK, France, Italy, Spain, Russia, Others, Asia-Pacific (Covered in Chapter 8 and 13), China, Japan, South Korea, Australia, India, Southeast Asia, Others, Middle East and Africa (Covered in Chapter 9 and 13), Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Others, South America (Covered in Chapter 10 and 13), Brazil, Argentina, Columbia, Chile, Others

Years considered for this report:, Historical Years: 2015-2019, Base Year: 2019, Estimated Year: 2020, Forecast Period: 2020-2026

Some Point of Table of Content:

Chapter One: Report Overview

Chapter Two: Global Market Growth Trends

Chapter Three: Value Chain of Stem Cell Banking Market

Chapter Four: Players Profiles

Chapter Five: Global Stem Cell Banking Market Analysis by Regions

[emailprotected]https://www.arcognizance.com/purchase/1315141

Chapter Six: North America Stem Cell Banking Market Analysis by Countries

Chapter Seven: Europe Stem Cell Banking Market Analysis by Countries

Chapter Eight: Asia-Pacific Stem Cell Banking Market Analysis by Countries

Chapter Nine: Middle East and Africa Stem Cell Banking Market Analysis by Countries

Chapter Ten: South America Stem Cell Banking Market Analysis by Countries

Chapter Eleven: Global Stem Cell Banking Market Segment by Types

Chapter Twelve: Global Stem Cell Banking Market Segment by Applications12.1 Global Stem Cell Banking Sales, Revenue and Market Share by Applications (2015-2020)12.1.1 Global Stem Cell Banking Sales and Market Share by Applications (2015-2020)12.1.2 Global Stem Cell Banking Revenue and Market Share by Applications (2015-2020)12.2 Personalized Banking Applications Sales, Revenue and Growth Rate (2015-2020)12.3 Clinical Applications Sales, Revenue and Growth Rate (2015-2020)12.4 Hematopoietic Disorders Sales, Revenue and Growth Rate (2015-2020)12.5 Autoimmune Disorders Sales, Revenue and Growth Rate (2015-2020)12.6 Other Diseases Sales, Revenue and Growth Rate (2015-2020)12.7 Research Applications Sales, Revenue and Growth Rate (2015-2020)12.8 Disease Treatment Studies Sales, Revenue and Growth Rate (2015-2020)12.9 Life Science Research Sales, Revenue and Growth Rate (2015-2020)12.10 Drug Discovery Sales, Revenue and Growth Rate (2015-2020)

Chapter Thirteen: Stem Cell Banking Market Forecast by Regions (2020-2026) continue

List of tablesList of Tables and FiguresTable Global Stem Cell Banking Market Size Growth Rate by Type (2020-2026)Figure Global Stem Cell Banking Market Share by Type in 2019 & 2026Figure Placental Stem Cells (PSCs) FeaturesFigure Human Embryo-derived Stem Cells (HESCs) FeaturesFigure Bone Marrow-derived Stem Cells (BMSCs) FeaturesFigure Adipose Tissue-derived Stem Cells (ADSCs) FeaturesFigure Dental Pulp-derived Stem Cells (DPSCs) FeaturesFigure Other Stem Cell Sources FeaturesTable Global Stem Cell Banking Market Size Growth by Application (2020-2026)Figure Global Stem Cell Banking Market Share by Application in 2019 & 2026Figure Personalized Banking Applications DescriptionFigure Clinical Applications DescriptionFigure Hematopoietic Disorders DescriptionFigure Autoimmune Disorders DescriptionFigure Other Diseases DescriptionFigure Research Applications DescriptionFigure Disease Treatment Studies DescriptionFigure Life Science Research DescriptionFigure Drug Discovery DescriptionFigure Global COVID-19 Status OverviewTable Influence of COVID-19 Outbreak on Stem Cell Banking Industry DevelopmentTable SWOT AnalysisFigure Porters Five Forces AnalysisFigure Global Stem Cell Banking Market Size and Growth Rate 2015-2026Table Industry NewsTable Industry PoliciesFigure Value Chain Status of Stem Cell BankingFigure Production Process of Stem Cell BankingFigure Manufacturing Cost Structure of Stem Cell BankingFigure Major Company Analysis (by Business Distribution Base, by Product Type)Table Downstream Major Customer Analysis (by Region)Table Boyalife ProfileTable Boyalife Production, Value, Price, Gross Margin 2015-2020Table StemCyte ProfileTable StemCyte Production, Value, Price, Gross Margin 2015-2020Table Crioestaminal ProfileTable Crioestaminal Production, Value, Price, Gross Margin 2015-2020Table Esperite ProfileTable Esperite Production, Value, Price, Gross Margin 2015-2020Table Americord ProfileTable Americord Production, Value, Price, Gross Margin 2015-2020Table Cryo-cell ProfileTable Cryo-cell Production, Value, Price, Gross Margin 2015-2020Table PBKM FamiCord ProfileTable PBKM FamiCord Production, Value, Price, Gross Margin 2015-2020Table Beikebiotech ProfileTable Beikebiotech Production, Value, Price, Gross Margin 2015-2020Table PacifiCord ProfileTable PacifiCord Production, Value, Price, Gross Margin 2015-2020Table RMS Regrow ProfileTable RMS Regrow Production, Value, Price, Gross Margin 2015-2020Table Stemade Biotech ProfileTable Stemade Biotech Production, Value, Price, Gross Margin 2015-2020Table Krio ProfileTable Krio Production, Value, Price, Gross Margin 2015-2020Table CCBC ProfileTable CCBC Production, Value, Price, Gross Margin 2015-2020Table Cordlife Group ProfileTable Cordlife Group Production, Value, Price, Gross Margin 2015-2020Table Cellsafe Biotech Group ProfileTable Cellsafe Biotech Group Production, Value, Price, Gross Margin 2015-2020Table Vcanbio ProfileTable Vcanbio Production, Value, Price, Gross Margin 2015-2020Table Familycord ProfileTable Familycord Production, Value, Price, Gross Margin 2015-2020Table ViaCord ProfileTable ViaCord Production, Value, Price, Gross Margin 2015-2020Table Cells4life ProfileTable Cells4life Production, Value, Price, Gross Margin 2015-2020Table LifeCell ProfileTable LifeCell Production, Value, Price, Gross Margin 2015-2020Table CBR ProfileTable CBR Production, Value, Price, Gross Margin 2015-2020Table Cryo Stemcell ProfileTable Cryo Stemcell Production, Value, Price, Gross Margin 2015-2020Figure Global Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Global Stem Cell Banking Revenue ($) and Growth (2015-2020)Table Global Stem Cell Banking Sales by Regions (2015-2020)Table Global Stem Cell Banking Sales Market Share by Regions (2015-2020)Table Global Stem Cell Banking Revenue ($) by Regions (2015-2020)Table Global Stem Cell Banking Revenue Market Share by Regions (2015-2020)Table Global Stem Cell Banking Revenue Market Share by Regions in 2015Table Global Stem Cell Banking Revenue Market Share by Regions in 2019Figure North America Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Europe Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Asia-Pacific Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Middle East and Africa Stem Cell Banking Sales and Growth Rate (2015-2020)Figure South America Stem Cell Banking Sales and Growth Rate (2015-2020)Figure North America Stem Cell Banking Revenue ($) and Growth (2015-2020)Table North America Stem Cell Banking Sales by Countries (2015-2020)Table North America Stem Cell Banking Sales Market Share by Countries (2015-2020)Figure North America Stem Cell Banking Sales Market Share by Countries in 2015Figure North America Stem Cell Banking Sales Market Share by Countries in 2019Table North America Stem Cell Banking Revenue ($) by Countries (2015-2020)Table North America Stem Cell Banking Revenue Market Share by Countries (2015-2020)Figure North America Stem Cell Banking Revenue Market Share by Countries in 2015Figure North America Stem Cell Banking Revenue Market Share by Countries in 2019Figure United States Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Canada Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Mexico Stem Cell Banking Sales and Growth (2015-2020)Figure Europe Stem Cell Banking Revenue ($) Growth (2015-2020)Table Europe Stem Cell Banking Sales by Countries (2015-2020)Table Europe Stem Cell Banking Sales Market Share by Countries (2015-2020)Figure Europe Stem Cell Banking Sales Market Share by Countries in 2015Figure Europe Stem Cell Banking Sales Market Share by Countries in 2019Table Europe Stem Cell Banking Revenue ($) by Countries (2015-2020)Table Europe Stem Cell Banking Revenue Market Share by Countries (2015-2020)Figure Europe Stem Cell Banking Revenue Market Share by Countries in 2015Figure Europe Stem Cell Banking Revenue Market Share by Countries in 2019Figure Germany Stem Cell Banking Sales and Growth Rate (2015-2020)Figure UK Stem Cell Banking Sales and Growth Rate (2015-2020)Figure France Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Italy Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Spain Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Russia Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Asia-Pacific Stem Cell Banking Revenue ($) and Growth (2015-2020)Table Asia-Pacific Stem Cell Banking Sales by Countries (2015-2020)Table Asia-Pacific Stem Cell Banking Sales Market Share by Countries (2015-2020)Figure Asia-Pacific Stem Cell Banking Sales Market Share by Countries in 2015Figure Asia-Pacific Stem Cell Banking Sales Market Share by Countries in 2019Table Asia-Pacific Stem Cell Banking Revenue ($) by Countries (2015-2020)Table Asia-Pacific Stem Cell Banking Revenue Market Share by Countries (2015-2020)Figure Asia-Pacific Stem Cell Banking Revenue Market Share by Countries in 2015Figure Asia-Pacific Stem Cell Banking Revenue Market Share by Countries in 2019Figure China Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Japan Stem Cell Banking Sales and Growth Rate (2015-2020)Figure South Korea Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Australia Stem Cell Banking Sales and Growth Rate (2015-2020)Figure India Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Southeast Asia Stem Cell Banking Sales and Growth Rate (2015-2020)Figure Middle East and Africa Stem Cell Banking Revenue ($) and Growth (2015-2020)continue

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

Here is the original post:
Impact Of Covid-19 on Stem Cell Banking Market 2020 Industry Challenges, by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026...

Recommendation and review posted by Bethany Smith